Health
Excel
Liver Diseases Dataset – Hepatic Disorders & Conditions Database
Liver Diseases Dataset
The Liver Diseases Dataset is a structured medical database containing a comprehensive list of conditions affecting the liver and hepatobiliary system.
The liver plays a critical role in metabolism, detoxification, and digestion. Liver diseases such as hepatitis, fatty liver disease, and cirrhosis are major global health concerns. This dataset provides organised information to support medical research, healthcare analytics, and application development.
Each record includes key clinical details such as disease descriptions, affected liver structures, common symptoms, severity levels, and treatment approaches.
The dataset has been cleaned and structured for easy integration into spreadsheets, databases, and analytical tools.
It is ideal for hepatology research, healthcare developers, educators, and data scientists working with liver health data.
Dataset Contents
The dataset includes fields such as:
- Disease / Condition Name
- Description
- Affected Area (Liver, Bile Ducts, Hepatobiliary System)
- Common Symptoms
- Severity Level
- Disease Category
- Risk Factors
- Treatment / Management
Example Conditions Included
- Hepatitis A, B, and C
- Fatty Liver Disease (NAFLD / AFLD)
- Liver Cirrhosis
- Liver Cancer (Hepatocellular Carcinoma)
- Alcoholic Liver Disease
- Liver Fibrosis
- Biliary Atresia
- Cholestasis
- Autoimmune Hepatitis
- Hemochromatosis
...and many more liver-related conditions.
Data Preview
12 columns
25 rows shown
| No. | Disease Name | Category | Primary Cause / Etiology | Prevalence | Age of Onset | Key Symptoms | Affected Organ(s) | Diagnostic Method | Treatment Approach | Prognosis | ICD-10 Code | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ▸ Viral Hepatitis | |||||||||||
| 2 | 1 | Acute Hepatitis B | Viral Hepatitis | Hepatitis B virus (HBV) is a partially double-stranded DNA hepadnavirus that replicates through reverse transcription of a pregenomic RNA intermediate. Transmission occurs through percutaneous or mucosal exposure to infected blood and body fluids, including sexual contact, perinatal transmission, injection drug use, and occupational needlestick exposure. HBV enters hepatocytes via the sodium taurocholate cotransporting polypeptide (NTCP) receptor and establishes covalently closed circular DNA (cccDNA) in the hepatocyte nucleus, which serves as the template for viral transcription. Hepatocellular injury in acute HBV is predominantly immune-mediated through vigorous CD8+ cytotoxic T-cell and NK cell responses against HBV-expressing hepatocytes, with the strength of immune response determining both disease severity and likelihood of viral clearance. | Approximately 296 million people worldwide are living with chronic HBV infection (WHO 2022), with an estimated 1.5 million new infections annually. Prevalence is highest in the WHO Western Pacific and African regions, where 6-8% of the adult population is HBsAg-positive. In the United States and Western Europe, prevalence is 0.3-0.5%, with acute HBV incidence approximately 1-2 per 100,000 following widespread vaccination. Universal infant HBV vaccination programs have dramatically reduced new infections, with global childhood prevalence falling from 4.7% pre-vaccine to under 1%. | The risk of chronicity is inversely related to age at infection: perinatal transmission leads to chronic infection in 90% of cases, infection in children aged 1-5 years leads to chronicity in 25-50%, while adult-acquired infection becomes chronic in less than 5% of immunocompetent individuals. Acute symptomatic hepatitis B primarily affects adolescents and adults, with peak incidence in the 20-49 age group. In endemic areas, most infections occur perinatally or in early childhood and are typically asymptomatic. | The incubation period is 45-180 days (mean 75 days). Approximately 70% of adults with acute HBV have subclinical or anicteric hepatitis. Symptomatic patients develop a prodromal serum-sickness-like illness with fever, arthralgia, urticarial rash, and malaise, followed by anorexia, nausea, right upper quadrant pain, and jaundice. ALT levels typically rise to 1000-3000 IU/L. Fulminant hepatic failure develops in approximately 0.1-0.5% of acute cases, characterized by coagulopathy, encephalopathy, and multiorgan failure. Extrahepatic manifestations include polyarteritis nodosa, glomerulonephritis, and aplastic anemia. | Liver (hepatocytes); immune system; kidneys (membranous nephropathy, polyarteritis nodosa); joints (immune-complex arthritis); skin (urticaria, papular acrodermatitis of childhood/Gianotti-Crosti syndrome) | Serologic diagnosis follows a characteristic pattern: HBsAg appears first (1-10 weeks after exposure), followed by HBeAg and high HBV DNA levels indicating active viral replication. Anti-HBc IgM is the hallmark of acute infection and is critical for diagnosis during the window period when HBsAg has cleared but anti-HBs has not yet appeared. HBV DNA quantification by real-time PCR confirms viremia. Markedly elevated ALT/AST (typically 10-100 times ULN) with elevated bilirubin in icteric cases. Resolution is indicated by HBsAg clearance, appearance of anti-HBs, and normalization of ALT within 6 months. | Treatment of acute HBV is primarily supportive, as over 95% of immunocompetent adults achieve spontaneous clearance. Antiviral therapy with nucleos(t)ide analogues (entecavir 0.5 mg daily or tenofovir disoproxil 300 mg daily) is indicated for severe acute hepatitis with coagulopathy (INR >1.5), protracted course exceeding 4 weeks, or immunosuppressed patients per AASLD 2018 guidelines. Fulminant hepatic failure requires intensive care and urgent liver transplantation evaluation. Post-exposure prophylaxis with hepatitis B immunoglobulin (HBIG) and HBV vaccine should be administered within 24 hours of exposure. Prevention through universal HBV vaccination (3-dose series: 0, 1, 6 months) is the cornerstone strategy. | Good - Over 95% of immunocompetent adults achieve complete spontaneous recovery with clearance of HBsAg and development of protective anti-HBs antibodies within 6 months. Fulminant hepatic failure occurs in 0.1-0.5% and carries a mortality rate of 60-80% without liver transplantation. Progression to chronic hepatitis B occurs in less than 5% of adult-acquired infections. Recovery confers lifelong immunity, although trace cccDNA may persist in hepatocytes indefinitely (occult HBV infection). Patients who recover should still be monitored if undergoing immunosuppressive therapy, as reactivation can occur. | B16.9 |
| 3 | 2 | Acute Hepatitis C | Viral Hepatitis | Hepatitis C virus (HCV) is an enveloped, single-stranded positive-sense RNA flavivirus transmitted primarily through percutaneous blood exposure. HCV displays remarkable genetic diversity with 8 genotypes and over 90 subtypes, which has complicated vaccine development. The virus enters hepatocytes through a multi-step process involving CD81, scavenger receptor class B type 1 (SR-BI), claudin-1, and occludin receptors. Acute HCV infection elicits both innate (interferon) and adaptive (CD4+ helper and CD8+ cytotoxic T-cell) immune responses; spontaneous viral clearance occurs in 15-45% of cases, primarily driven by vigorous, multi-specific T-cell responses, while viral escape mutations and T-cell exhaustion contribute to chronicity in the majority. | An estimated 58 million people worldwide have chronic HCV infection, with approximately 1.5 million new infections annually (WHO 2023). In the United States, the estimated incidence of acute HCV increased from 2010 to 2020 due to the opioid epidemic and injection drug use, with approximately 66,700 new infections in 2020 (CDC). HCV genotype 1 is the most prevalent worldwide (46% of all infections), followed by genotype 3 (30%). High-prevalence countries include Egypt (genotype 4), Pakistan (genotype 3), and China (genotype 1b). | Acute HCV can occur at any age. In the United States, the highest incidence is among young adults aged 20-39 years, driven by injection drug use related to the opioid epidemic. A second peak is observed in adults over 60 (baby boomer cohort) who were infected decades ago through medical procedures, blood transfusions (before 1992 screening), or other exposures. In endemic countries, new infections may occur at younger ages through healthcare-associated transmission. | Acute HCV is asymptomatic in 70-80% of cases, which contributes to underdiagnosis. When symptoms occur, they develop 2-12 weeks after exposure and include fatigue, malaise, anorexia, nausea, right upper quadrant pain, and jaundice (20-30% of symptomatic cases). ALT levels rise to 10-20 times ULN, typically peaking 8-12 weeks post-exposure. Fulminant hepatic failure is exceedingly rare (<0.1%) in acute HCV. Paradoxically, symptomatic acute HCV (particularly jaundice) is associated with higher rates of spontaneous clearance, likely reflecting a more vigorous immune response. | Liver (hepatocytes); immune system (cryoglobulinemia, lymphoproliferative disorders); kidneys (membranoproliferative glomerulonephritis); blood vessels (vasculitis) | Diagnosis of acute HCV requires demonstration of HCV RNA (by PCR) with or without anti-HCV antibodies, in the context of a compatible clinical presentation and recent exposure. Anti-HCV antibodies may be negative in early acute infection (seronegative window up to 8-12 weeks), making HCV RNA testing essential. Seroconversion (new-onset anti-HCV positivity in a previously seronegative individual) is the most definitive diagnostic criterion. ALT elevation precedes antibody development and may be the first laboratory abnormality detected. HCV genotyping guides treatment selection if therapy is initiated. Quantitative HCV RNA levels do not reliably predict spontaneous clearance or treatment response in acute infection. | Current AASLD/IDSA guidelines recommend treatment of acute HCV with direct-acting antivirals (DAAs) using the same pan-genotypic regimens as chronic HCV. Monitoring for spontaneous clearance can be considered for 12-16 weeks before initiating treatment per some guidelines (EASL). Preferred regimens include sofosbuvir/velpatasvir (Epclusa) 400/100 mg daily for 8 weeks or glecaprevir/pibrentasvir (Mavyret) 300/120 mg daily for 8 weeks. Cure rates (SVR12: sustained virologic response 12 weeks post-treatment) exceed 95% with DAA therapy. Post-exposure prophylaxis with DAAs is under investigation but not yet standard practice. All persons with identified acute HCV should be tested for HIV and HBV co-infection. | Good - Spontaneous viral clearance occurs in 15-45% of acute HCV cases within 6 months, more commonly in symptomatic patients, women, younger individuals, those with IL28B CC genotype, and immunocompetent hosts. For the 55-85% who progress to chronic infection, DAA treatment achieves cure (SVR12) in over 95% of cases. Without treatment, chronic HCV develops insidiously, leading to cirrhosis in 15-30% over 20-30 years. Fulminant hepatic failure from acute HCV is extremely rare. Early DAA treatment during the acute phase prevents chronicity and long-term complications in essentially all treated patients. | B17.1 |
| 4 | 3 | Adenovirus Hepatitis | Viral Hepatitis | Adenoviruses are non-enveloped double-stranded DNA viruses (family Adenoviridae) with over 100 types classified into 7 species (A-G). Adenovirus hepatitis is most commonly caused by species C (types 1, 2, 5) and species B (types 3, 7) and occurs primarily in immunocompromised patients, particularly pediatric hematopoietic stem cell transplant recipients and solid organ transplant recipients. The virus directly infects hepatocytes, causing coagulative necrosis with characteristic smudge cells (amphophilic intranuclear inclusions that fill and distort the nucleus). In immunocompetent hosts, adenovirus hepatitis is very rare and typically self-limiting, though severe cases and outbreaks of acute hepatitis of unknown etiology in children (2022) raised concern about potential adenovirus involvement. | Adenovirus is ubiquitous, with most children seropositive for multiple serotypes by age 10. Adenovirus hepatitis is rare in immunocompetent individuals but has an incidence of 6-12% in pediatric HSCT recipients, representing one of the most serious viral complications of transplantation. In solid organ transplant recipients, adenovirus hepatitis is less common (1-5%) but particularly affects liver transplant recipients through donor-derived infection. The 2022 global cluster of acute hepatitis of unknown etiology in children led to investigation of adenovirus type 41 as a potential cause, though definitive causality remains debated. | Adenovirus hepatitis predominantly affects immunocompromised children and young adults post-transplantation, with the highest incidence in the first 100 days after HSCT. Pediatric liver transplant recipients are particularly vulnerable due to donor-derived adenovirus infection. Neonates can develop severe disseminated adenovirus disease including hepatitis. In immunocompetent hosts, adenovirus hepatitis is extremely rare at any age, though the 2022 outbreak primarily affected otherwise healthy children aged 1-5 years. | In immunocompromised patients, adenovirus hepatitis presents with rapidly rising transaminases (often >10-20 times ULN), fever, and hepatomegaly. Progression to liver failure with coagulopathy and encephalopathy can occur over days. Concurrent adenovirus involvement of other organs (pneumonitis, hemorrhagic cystitis, colitis, nephritis) is common in disseminated disease. In HSCT recipients, adenovirus disease may present with viremia before organ-specific symptoms develop. In the 2022 pediatric cluster, affected children presented with acute hepatitis, jaundice, and liver failure requiring transplantation in some cases. Diarrhea, vomiting, and respiratory symptoms may precede hepatic involvement. | Liver (hepatocytes); gastrointestinal tract (gastroenteritis); respiratory tract (pneumonitis); urinary tract (hemorrhagic cystitis); kidneys (nephritis); bone marrow (graft failure in HSCT); eyes (keratoconjunctivitis) | Adenovirus DNA quantification by PCR in blood is the standard for diagnosing disseminated disease in immunocompromised patients, with regular monitoring (weekly) in high-risk transplant recipients. Liver biopsy shows coagulative necrosis with characteristic smudge cells and can confirm the diagnosis by immunohistochemistry or in situ hybridization. Adenovirus typing by PCR or sequencing identifies the specific serotype. In immunocompetent patients, nasopharyngeal or stool adenovirus PCR may be positive but does not necessarily confirm hepatotropism. Electron microscopy can visualize characteristic viral particles. ALT/AST elevation may be dramatic (>5000 IU/L) in severe cases. | Cidofovir (5 mg/kg IV weekly with probenecid and saline hydration to prevent nephrotoxicity) is the standard antiviral for severe adenovirus disease, though evidence is limited to case series. Brincidofovir (oral lipid conjugate of cidofovir) was developed for adenovirus and shows improved oral bioavailability with less nephrotoxicity but has not achieved FDA approval for this indication. Reduction of immunosuppressive therapy is essential when possible. Adoptive transfer of adenovirus-specific cytotoxic T lymphocytes (viral-specific T cells) is an emerging and promising therapy in HSCT recipients, achieving viral clearance in 70-80% of cases. Intravenous immunoglobulin (IVIG) may provide passive antibody protection. Liver transplantation may be necessary for fulminant hepatic failure. | Poor - In immunocompromised patients, disseminated adenovirus hepatitis carries a mortality rate of 50-80% in HSCT recipients without effective treatment. Early detection through surveillance monitoring and prompt treatment with cidofovir improves outcomes. Adoptive T-cell therapy has shown encouraging results, reducing mortality to 20-30% in treated patients. In immunocompetent children with severe adenovirus hepatitis (as in the 2022 cluster), most recover but some required liver transplantation. Risk factors for mortality include high viral load (>10^6 copies/mL), disseminated disease, lack of immune reconstitution, and delay in treatment initiation. | B34.0 |
| 5 | 4 | Chronic Hepatitis B | Viral Hepatitis | Chronic hepatitis B (CHB) is defined by the persistence of HBsAg for more than 6 months, resulting from failure of the immune system to clear HBV infection. The virus maintains a stable nuclear reservoir of covalently closed circular DNA (cccDNA) within hepatocyte nuclei, which is resistant to current antiviral therapies and serves as the template for ongoing viral transcription. CHB progresses through four immunologic phases: immune-tolerant (HBeAg-positive chronic infection with high viral load and normal ALT), immune-active (HBeAg-positive chronic hepatitis with elevated ALT and liver inflammation), inactive carrier (HBeAg-negative chronic infection with low viral load and normal ALT after HBeAg seroconversion), and HBeAg-negative chronic hepatitis (reactivation phase with precore/basal core promoter mutants). Persistent hepatic necroinflammation drives progressive fibrosis, cirrhosis, and hepatocarcinogenesis through both direct viral oncogenic mechanisms (HBV DNA integration into host genome) and indirect mechanisms (chronic inflammation, oxidative stress, regenerative hyperplasia). | Approximately 296 million people worldwide have chronic HBV infection, with 820,000-880,000 deaths annually from HBV-related cirrhosis and hepatocellular carcinoma. The highest prevalence is in the WHO Western Pacific Region (6.2%) and African Region (6.1%), with intermediate prevalence in the Eastern Mediterranean and Southeast Asia regions. In the United States, an estimated 2.2 million persons have chronic HBV, predominantly among foreign-born individuals from endemic countries. HBV is the leading cause of hepatocellular carcinoma globally, accounting for approximately 50% of HCC cases worldwide. | The age at infection is the primary determinant of chronicity risk: perinatal infection leads to chronicity in approximately 90%, early childhood infection in 25-50%, and adult infection in less than 5%. In highly endemic areas, most chronic HBV carriers acquired the infection perinatally or in early childhood. The immune-tolerant phase may persist for decades in perinatally-infected individuals, with active hepatitis typically developing in the third to fourth decade of life. HBeAg seroconversion occurs at a rate of approximately 5-15% per year in the immune-active phase. | Many patients with CHB are asymptomatic for years to decades, identified incidentally through screening. When symptoms develop, they include fatigue, malaise, right upper quadrant discomfort, and occasionally nausea. Acute flares of hepatitis (ALT elevation >5 times ULN) can occur during immune-active phases or during HBeAg seroconversion, mimicking acute hepatitis. Extrahepatic manifestations include polyarteritis nodosa, membranous nephropathy, cryoglobulinemia, and aplastic anemia. Patients with advancing fibrosis develop signs of portal hypertension including splenomegaly, thrombocytopenia, and eventually ascites, variceal bleeding, and hepatic encephalopathy. HCC may develop even in the absence of cirrhosis, particularly in African and Asian patients with longstanding high viral loads. | Liver (hepatocytes, stellate cells in fibrosis); kidneys (membranous nephropathy, polyarteritis nodosa); immune system; blood vessels (polyarteritis nodosa); bone marrow (aplastic anemia) | Diagnosis requires HBsAg positivity for more than 6 months. Complete serologic profiling includes HBeAg/anti-HBe status, quantitative HBV DNA by PCR, and anti-HDV screening. ALT levels guide treatment decisions but may be normal despite significant fibrosis. Liver fibrosis assessment is essential: non-invasive methods include transient elastography (FibroScan), FIB-4 index, APRI score, and serum fibrosis biomarkers. Liver biopsy remains the gold standard for grading necroinflammation (Knodell/Ishak score) and staging fibrosis. HCC surveillance with abdominal ultrasound with or without alpha-fetoprotein every 6 months is recommended for at-risk patients per AASLD guidelines. | First-line antiviral therapy per AASLD 2018 and EASL 2017 guidelines includes nucleos(t)ide analogues with high barrier to resistance: entecavir (0.5 mg daily for treatment-naive, 1 mg for lamivudine-experienced) or tenofovir disoproxil fumarate (300 mg daily) or tenofovir alafenamide (25 mg daily, preferred in patients with renal or bone disease risk). Treatment is indicated for immune-active disease (elevated ALT plus HBV DNA >20,000 IU/mL if HBeAg-positive or >2,000 IU/mL if HBeAg-negative), significant fibrosis (F2 or greater), cirrhosis regardless of ALT/DNA level, and selected special populations. Pegylated interferon alfa-2a (180 mcg weekly for 48 weeks) offers a finite treatment course with higher rates of HBsAg loss (3-7% at 1 year) but significant side effects. Functional cure (HBsAg loss with or without anti-HBs seroconversion) is achieved in less than 1% per year with NUC therapy. Novel therapies targeting cccDNA silencing, capsid assembly, and HBsAg secretion are in clinical trials. | Variable - The natural history varies widely depending on the phase of infection, host immune response, HBV genotype, and presence of cofactors. Without treatment, 15-40% of patients with chronic HBV develop cirrhosis, hepatocellular carcinoma, or end-stage liver disease. Annual incidence of cirrhosis is 2-6% in HBeAg-positive patients and 8-10% in those with active HBeAg-negative disease. HCC develops at a rate of 0.5-1% per year in non-cirrhotic CHB patients and 2-5% per year in those with established cirrhosis. Long-term nucleos(t)ide analogue therapy can halt or reverse fibrosis progression, reduce HCC risk by 50-70%, and improve overall survival. Functional cure (HBsAg loss) is associated with the best long-term outcomes but is achieved in only 1-3% of treated patients over 5 years. | B18.1 |
| 6 | 5 | Chronic Hepatitis C | Viral Hepatitis | Chronic hepatitis C (CHC) is defined by persistence of HCV RNA for more than 6 months after initial infection, resulting from the failure of host immune responses to clear the virus. HCV replicates with high mutation rates (lacking proofreading polymerase activity), generating quasispecies diversity that enables viral escape from neutralizing antibodies and T-cell recognition. Chronic hepatic inflammation is driven by ongoing immune responses to persistent virus, with activation of hepatic stellate cells leading to progressive fibrosis through TGF-beta, PDGF, and connective tissue growth factor signaling. HCV also promotes hepatocarcinogenesis through both indirect mechanisms (chronic inflammation, fibrosis, oxidative stress) and direct viral protein effects (NS5A and core protein interactions with cell growth and apoptosis pathways), with HCC developing even in the absence of cirrhosis in rare cases. | Approximately 58 million people worldwide have chronic HCV infection, making it a leading cause of chronic liver disease, cirrhosis, HCC, and liver transplantation globally. In the United States, an estimated 2.4 million people have chronic HCV, with the highest prevalence among the baby boomer cohort (born 1945-1965) and increasing prevalence among young adults who inject drugs. HCV genotype 1 accounts for 75% of US infections. Chronic HCV accounts for approximately 25% of HCC cases globally and is the leading indication for liver transplantation in many Western countries. | Chronic HCV affects all age groups, reflecting the diverse modes and timing of acquisition. In the United States, a bimodal age distribution exists: the largest cohort comprises individuals born 1945-1965 who were infected through blood transfusion, healthcare exposure, or drug use decades ago; a second growing cohort comprises young adults aged 20-39 with injection drug use. In endemic countries, infections may occur at any age through healthcare-associated or household transmission. Disease progression to significant fibrosis typically takes 20-30 years from initial infection. | Most patients with chronic HCV are asymptomatic or have nonspecific symptoms such as fatigue, malaise, mild cognitive impairment (brain fog), myalgia, and arthralgia. Extrahepatic manifestations affect 40-74% of patients and include mixed cryoglobulinemia (type II/III) causing vasculitis, palpable purpura, membranoproliferative glomerulonephritis, peripheral neuropathy, and non-Hodgkin B-cell lymphoma. Other extrahepatic associations include type 2 diabetes mellitus, lichen planus, porphyria cutanea tarda, sicca syndrome, and insulin resistance. As fibrosis progresses to cirrhosis, symptoms of portal hypertension develop: ascites, variceal bleeding, hepatic encephalopathy, jaundice, spider angiomata, palmar erythema, and muscle wasting. | Liver (hepatocytes, stellate cells, Kupffer cells); kidneys (membranoproliferative GN, cryoglobulinemic nephropathy); blood vessels (cryoglobulinemic vasculitis); hematologic/lymphatic system (B-cell NHL, mixed cryoglobulinemia); endocrine system (type 2 diabetes, thyroid disorders); skin (porphyria cutanea tarda, lichen planus); nervous system (peripheral neuropathy) | Diagnosis requires anti-HCV antibody screening (by enzyme immunoassay) followed by confirmatory HCV RNA testing by quantitative PCR. Reflex testing (automatic HCV RNA if antibody positive) is recommended to streamline diagnosis. HCV genotyping is performed to guide treatment selection, though pan-genotypic regimens have reduced its importance. Liver fibrosis staging is essential and uses non-invasive methods: FibroScan (transient elastography) with thresholds of <7.1 kPa for F0-F1 and >12.5 kPa for F4, FIB-4 index, and APRI score. Liver biopsy is reserved for discordant non-invasive results or suspected concomitant liver disease. HCC surveillance (ultrasound every 6 months) is recommended for patients with cirrhosis or advanced fibrosis (F3) per AASLD guidelines. | Direct-acting antiviral (DAA) therapy has revolutionized HCV treatment, achieving cure rates (SVR12) exceeding 95% across all genotypes. Pan-genotypic regimens include: sofosbuvir/velpatasvir (Epclusa) 400/100 mg daily for 12 weeks; glecaprevir/pibrentasvir (Mavyret) 300/120 mg daily for 8 weeks (treatment-naive without cirrhosis) or 12 weeks (with compensated cirrhosis). For decompensated cirrhosis (Child-Pugh B/C), sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir is used (protease inhibitors are contraindicated in decompensated disease). Treatment is recommended for all patients with chronic HCV regardless of fibrosis stage per AASLD/IDSA and EASL guidelines. Post-SVR follow-up includes continued HCC surveillance for patients with advanced fibrosis/cirrhosis, as HCC risk persists despite cure (reduced by 71% but not eliminated). | Good - SVR12 (virologic cure) is achieved in over 95% of treated patients with current DAA regimens. Achieving SVR significantly improves all-cause mortality, liver-related mortality, HCC risk (71% reduction), and extrahepatic manifestations. Fibrosis regression occurs in 40-80% of patients post-SVR, including reversal of cirrhosis in some cases. However, patients with established cirrhosis at the time of cure retain a residual HCC risk of 1-3% per year, necessitating ongoing surveillance. Reinfection can occur (1-5% per year in high-risk populations) as SVR does not confer sterilizing immunity. Without treatment, 15-30% of CHC patients develop cirrhosis over 20-30 years, with annual HCC rates of 1-4% once cirrhosis is established. | B18.2 |
| 7 | 6 | Chronic Hepatitis E (Immunocompromised) | Viral Hepatitis | Chronic HEV infection is defined by persistence of HEV RNA for more than 3 months (some guidelines use 6 months) and occurs exclusively in immunocompromised individuals, almost always with HEV genotype 3 (rarely genotype 4). At-risk populations include solid organ transplant recipients (most commonly reported, particularly kidney and liver transplant), hematologic malignancies receiving chemotherapy, HIV-infected patients with CD4 counts below 200 cells/mm3, and patients on biologic immunosuppressive agents. The mechanism of chronicity involves impaired T-cell-mediated viral clearance due to pharmacologic or disease-related immunosuppression, allowing persistent HEV replication. Chronic HEV can cause rapidly progressive hepatic fibrosis, with cirrhosis developing in approximately 10% of cases within 2 years. | The prevalence of chronic HEV among solid organ transplant recipients in Europe is estimated at 1-2%, with higher rates in regions with high pork consumption and HEV genotype 3 endemicity. In France and the Netherlands, where pork products are widely consumed, HEV seroprevalence among transplant recipients is 14-25%, with chronic infection in 2-3%. Chronic HEV is increasingly recognized among HIV-positive patients and those receiving cancer chemotherapy. The true prevalence is likely underestimated due to the historically low awareness and inconsistent screening practices. | Chronic HEV affects immunocompromised individuals at any age, with solid organ transplant recipients (mean age 50-60 years) being the best-characterized population. HIV-infected patients developing chronic HEV tend to be younger (30-50 years). Children receiving solid organ or bone marrow transplants can also develop chronic HEV. The risk is highest in the first year after transplantation when immunosuppression is most intense. | Most cases of chronic HEV are initially asymptomatic or mildly symptomatic, often discovered incidentally through persistent elevation of liver enzymes during routine post-transplant monitoring. When symptoms develop, they include fatigue, malaise, and mild right upper quadrant discomfort. Jaundice is less common than in acute HEV. Rapid fibrosis progression can occur silently, with some patients presenting with established cirrhosis. Extrahepatic manifestations occur in up to 30% and include neurological involvement (Guillain-Barre syndrome, neuralgic amyotrophy, myositis), renal disease (membranoproliferative GN, cryoglobulinemia), and hematologic disorders. | Liver (hepatocytes, with progressive fibrosis and potential cirrhosis); nervous system (peripheral neuropathy, neuralgic amyotrophy); kidneys (glomerulonephritis); hematologic system | Diagnosis requires HEV RNA detection by RT-PCR in serum or stool, as antibody-based testing (anti-HEV IgM/IgG) has poor sensitivity in immunocompromised patients due to blunted humoral responses (up to 50% may be seronegative despite active viremia). HEV RNA testing should be performed on all immunocompromised patients with unexplained elevated liver enzymes. Quantitative HEV RNA is used for monitoring treatment response. Liver biopsy shows chronic hepatitis with portal and periportal inflammation, interface hepatitis, and fibrosis. Genotyping confirms genotype 3/4 (which can chronify) versus genotype 1/2 (which does not). Non-invasive fibrosis assessment by FibroScan is recommended for staging. | The first step in management is reduction of immunosuppressive therapy, particularly decreasing tacrolimus (by 25-50%) while maintaining adequate immunosuppression to prevent organ rejection. This achieves HEV clearance in approximately 30% of transplant recipients. If immunosuppression reduction fails or is not feasible, ribavirin monotherapy (600-800 mg daily, adjusted for renal function and hemoglobin) for at least 12 weeks is the standard treatment per EASL guidelines, achieving sustained virologic response in 80-85% of cases. Extended treatment (24 weeks or longer) may be needed for patients who do not clear HEV RNA by week 12. Pegylated interferon alfa can be used in non-transplant immunocompromised patients but is generally avoided in organ transplant recipients due to the risk of rejection. Sofosbuvir has shown in vitro activity against HEV but clinical data are limited and conflicting. | Variable - With appropriate management, the prognosis of chronic HEV is generally favorable. Reduction of immunosuppression alone achieves viral clearance in approximately 30% of cases. Ribavirin therapy achieves sustained virologic response in 80-85%, though relapse occurs in 10-15% requiring retreatment with prolonged courses. Without treatment, chronic HEV progresses to cirrhosis in approximately 10% within 2 years and can lead to hepatic decompensation and death. Relapse after ribavirin may be associated with the emergence of G1634R polymerase mutations conferring reduced ribavirin sensitivity. Overall survival is excellent with early diagnosis and treatment, but outcomes are worse in patients who develop cirrhosis before HEV is recognized. | B18.8 |
| 8 | 7 | Cytomegalovirus (CMV) Hepatitis | Viral Hepatitis | Cytomegalovirus (CMV) is a ubiquitous double-stranded DNA betaherpesvirus (HHV-5) that can cause hepatitis through both primary infection and reactivation. In immunocompetent hosts, primary CMV infection causes a self-limiting mononucleosis-like syndrome with hepatitis in 40-80% of cases, though ALT elevation is typically mild to moderate. In immunocompromised patients (solid organ transplant recipients, bone marrow transplant recipients, HIV/AIDS with CD4 <100), CMV hepatitis can be severe and life-threatening, resulting from either reactivation of latent virus or primary/reinfection. CMV replicates in hepatocytes, biliary epithelial cells, and hepatic sinusoidal endothelial cells, causing direct cytopathic injury characterized by cytomegalic cells with intranuclear inclusions (owl's eye appearance), as well as immune-mediated damage. | CMV seroprevalence ranges from 40-60% in developed countries to >90% in developing countries by adulthood. CMV hepatitis in immunocompetent adults accounts for approximately 2-5% of acute hepatitis cases in community studies. Among solid organ transplant recipients, CMV disease (including hepatitis) occurs in 8-30% without prophylaxis, with the highest risk in CMV-seronegative recipients receiving organs from seropositive donors (D+/R-). CMV hepatitis is the most common visceral organ involvement in CMV disease after transplantation. | CMV hepatitis can occur at any age. In immunocompetent hosts, primary CMV hepatitis typically presents in adolescents and young adults (15-35 years). In transplant recipients, CMV hepatitis most commonly occurs 1-6 months post-transplant (late-onset CMV disease beyond 6 months is increasingly recognized with prophylaxis). Congenital CMV infection can cause neonatal hepatitis and cholestasis in affected newborns. | In immunocompetent patients, CMV hepatitis presents as part of a mononucleosis-like syndrome with prolonged fever (>2 weeks), fatigue, malaise, myalgia, mild hepatomegaly, and mildly elevated transaminases (typically 2-5 times ULN). Jaundice is uncommon (5-10%) in immunocompetent CMV hepatitis. Atypical lymphocytosis is present in 50-70%. In immunocompromised patients, CMV hepatitis presents with fever, hepatomegaly, significantly elevated transaminases, and potentially granulomatous hepatitis. Cholestatic hepatitis with vanishing bile duct syndrome can occur. Severe cases in immunocompromised patients may progress to liver failure. | Liver (hepatocytes, biliary epithelium, sinusoidal endothelium); gastrointestinal tract (esophagitis, colitis); lungs (pneumonitis); eyes (retinitis); central nervous system (encephalitis); bone marrow (myelosuppression) | In immunocompetent patients, diagnosis is based on CMV IgM positivity with seroconversion (new CMV IgG positivity), supported by compatible clinical syndrome. CMV DNA quantification by PCR is the standard for diagnosing CMV disease in immunocompromised patients, with viral loads typically >1000-10,000 IU/mL. CMV pp65 antigenemia assay is an alternative but has been largely replaced by PCR. Liver biopsy shows characteristic cytomegalic cells with intranuclear (owl's eye) and intracytoplasmic inclusions, confirmed by immunohistochemistry for CMV antigens. ALT elevation is typically mild-moderate in immunocompetent (2-5x ULN) but can be more severe in immunocompromised patients. Heterophile antibody test (monospot) is negative, distinguishing CMV from EBV mononucleosis. | In immunocompetent patients, CMV hepatitis is self-limiting and requires only supportive care; antiviral therapy is not routinely recommended. In immunocompromised patients, treatment with intravenous ganciclovir (5 mg/kg IV twice daily for 14-21 days) is first-line, followed by oral valganciclovir (900 mg twice daily) step-down therapy. Foscarnet (90 mg/kg IV twice daily) is the alternative for ganciclovir-resistant CMV (UL97 kinase mutations). Cidofovir and letermovir are additional options. Reduction of immunosuppressive therapy should be attempted when possible. Prevention in transplant recipients includes universal prophylaxis with valganciclovir or preemptive monitoring with treatment initiated when viremia exceeds threshold levels. | Good - In immunocompetent patients, CMV hepatitis is self-limiting with complete recovery typically within 4-8 weeks, though fatigue may persist for months. Fulminant hepatic failure from CMV is exceedingly rare in immunocompetent adults but has been reported. In immunocompromised patients, CMV hepatitis carries a mortality rate of 10-20% if untreated but responds well to antiviral therapy, with virologic clearance in 80-90% of cases. Ganciclovir-resistant CMV (occurring in 5-10% of transplant patients on prolonged therapy) requires alternative agents and has a worse prognosis. Risk of CMV-related hepatic graft loss is low with appropriate treatment. | B25.1 |
| 9 | 8 | Epstein-Barr Virus (EBV) Hepatitis | Viral Hepatitis | Epstein-Barr virus (EBV/HHV-4) is a ubiquitous gammaherpesvirus that causes hepatitis as part of infectious mononucleosis or as an isolated hepatotropic infection. EBV infects B lymphocytes through the CD21 receptor and oropharyngeal epithelial cells, establishing lifelong latency in memory B cells. Hepatic involvement occurs through infiltration of activated CD8+ cytotoxic T cells (directed against EBV-infected B cells) into liver sinusoids and portal tracts, causing a characteristic sinusoidal lymphocytic infiltrate on biopsy. Direct EBV infection of hepatocytes is rare but has been demonstrated. Liver enzyme elevations occur in 80-90% of patients with infectious mononucleosis, though clinically significant hepatitis with jaundice occurs in only 5-10%. | EBV infects approximately 95% of the world's adult population. Infectious mononucleosis (the primary clinical manifestation in adolescents/young adults) has an incidence of 500-1000 per 100,000 per year in the 15-24 age group. Hepatitis with transaminase elevation occurs in 80-90% of mononucleosis cases, but jaundice develops in only 5-10%. EBV hepatitis is one of the most common causes of acute hepatitis in young adults in developed countries, second only to hepatitis A in some series. Severe EBV hepatitis and EBV-associated hemophagocytic lymphohistiocytosis (HLH) are more common in certain populations, particularly males with X-linked lymphoproliferative disease. | Primary EBV infection causing infectious mononucleosis and hepatitis is most common in adolescents and young adults (15-25 years) in developed countries, where delayed primary exposure occurs. In developing countries, primary EBV infection occurs in early childhood and is typically asymptomatic. Severe EBV hepatitis and EBV-HLH can occur at any age, with X-linked lymphoproliferative disease presenting in young males. Elderly patients with primary EBV infection may present with cholestatic hepatitis mimicking biliary obstruction. | In the context of infectious mononucleosis, hepatitis manifests as mild transaminase elevation (2-5 times ULN) accompanying the classic triad of fever, pharyngitis, and lymphadenopathy. ALT is typically higher than AST. Splenomegaly occurs in 50-60% and increases the risk of splenic rupture. Jaundice develops in 5-10% and is usually mild and self-limiting. Cholestatic hepatitis can occur, particularly in elderly patients, and may mimic biliary obstruction. Rare severe complications include fulminant hepatic failure, hemophagocytic lymphohistiocytosis (HLH), and splenic rupture. Post-transplant lymphoproliferative disorder (PTLD) in immunosuppressed patients may present with hepatic involvement. | Liver (sinusoidal infiltration by reactive lymphocytes); lymphatic system (lymphadenopathy, splenomegaly); pharynx/tonsils; hematologic system (hemolytic anemia, thrombocytopenia); spleen (splenomegaly, rupture risk); CNS (meningitis, encephalitis rarely) | Diagnosis of EBV hepatitis is based on serologic testing in the context of compatible clinical features. Heterophile antibody test (monospot) is 85-90% sensitive in adolescents/adults but may be negative in early illness and in children under 4. EBV-specific serologies (VCA IgM, VCA IgG, EA IgG, EBNA IgG) establish the timing of infection (acute vs. past vs. reactivation). EBV DNA quantification by PCR is used in immunocompromised patients and for suspected EBV-HLH or PTLD. Liver biopsy (rarely needed) shows characteristic sinusoidal lymphocytic infiltration with minimal hepatocellular necrosis. ALT is typically 2-5 times ULN; markedly elevated transaminases (>10 times ULN) should prompt consideration of alternative diagnoses or complications. | EBV hepatitis is self-limiting in immunocompetent individuals and treatment is supportive: rest, adequate hydration, analgesics/antipyretics (avoiding aspirin due to Reye syndrome risk in adolescents), and avoidance of contact sports for 4-8 weeks due to splenic rupture risk. Corticosteroids are not routinely recommended but may be considered for severe complications (airway obstruction, severe thrombocytopenia, hemolytic anemia, myocarditis). Antivirals (acyclovir, valacyclovir) reduce EBV oropharyngeal shedding but have not shown clinical benefit in mononucleosis or hepatitis. For EBV-associated HLH, treatment includes dexamethasone, etoposide, and cyclosporine per the HLH-2004 protocol. Post-transplant lymphoproliferative disorder requires reduction of immunosuppression, rituximab, and possibly chemotherapy. | Good - EBV hepatitis in immunocompetent patients is self-limiting with complete resolution of transaminase elevations within 4-8 weeks. Fulminant hepatic failure from EBV is exceedingly rare (incidence <0.01%) but can be fatal. Chronic active EBV infection with persistent hepatitis is rare and is associated with T/NK-cell lymphoproliferative disorders. EBV-associated HLH has a mortality rate of 40-50% despite treatment. Post-transplant lymphoproliferative disorder with hepatic involvement has a variable prognosis depending on histologic subtype and response to reduction of immunosuppression. Overall mortality from EBV hepatitis in immunocompetent patients approaches zero. | B27.09 |
| 10 | 9 | HIV-Associated Hepatitis | Viral Hepatitis | HIV-associated hepatitis encompasses the spectrum of liver disease directly attributable to HIV infection itself, excluding coinfection with hepatitis B/C viruses and drug-induced liver injury. HIV infects hepatic stellate cells, Kupffer cells, and possibly hepatocytes through CXCR4 and CCR5 coreceptors, promoting hepatic fibrosis through upregulation of TGF-beta, collagen production, and inhibition of stellate cell apoptosis. HIV-associated immune activation and microbial translocation (gut-associated lymphoid tissue depletion leading to increased bacterial lipopolysaccharide exposure) contribute to chronic hepatic inflammation. Additionally, HIV accelerates fibrosis progression in patients with coexisting liver diseases (viral hepatitis, NAFLD, alcohol) and antiretroviral therapy itself can cause hepatotoxicity through mitochondrial toxicity (NRTIs), hypersensitivity reactions (nevirapine, abacavir), and metabolic effects (protease inhibitors causing lipodystrophy and steatosis). | HIV infects approximately 39 million people worldwide (UNAIDS 2023). Liver disease is a leading cause of non-AIDS-related morbidity and mortality in HIV-positive individuals, accounting for 14-18% of deaths in the antiretroviral therapy era. Elevated liver enzymes are found in 40-60% of HIV-positive patients on ART. NAFLD prevalence is approximately 35-45% in HIV-positive populations, higher than the general population. HIV/HBV coinfection affects approximately 5-10% of HIV-positive individuals globally (higher in sub-Saharan Africa), and HIV/HCV coinfection affects approximately 6% globally (higher in PWID populations, up to 50-90%). | HIV-associated hepatitis affects all age groups with HIV infection. In developed countries, the mean age of HIV-positive individuals with significant liver disease is increasing due to ART-related longevity, with most liver-related complications occurring in patients aged 40-60 years. In sub-Saharan Africa, younger populations are affected due to earlier HIV acquisition. ART-related hepatotoxicity can occur at any time after treatment initiation, with some agents causing early hypersensitivity reactions (first 6-18 weeks) and others causing cumulative metabolic effects over years. | Clinical manifestations range from asymptomatic transaminase elevation to advanced liver disease with portal hypertension. HIV-associated NAFLD/NASH presents with hepatic steatosis and metabolic syndrome features exacerbated by ART-associated lipodystrophy and insulin resistance. ART-related hepatotoxicity presents with elevated transaminases, with patterns varying by drug class: NRTIs (didanosine, stavudine) cause mitochondrial toxicity with lactic acidosis and microvesicular steatosis; NNRTIs (nevirapine) cause hypersensitivity hepatitis in the first 18 weeks; protease inhibitors cause lipodystrophy and steatosis. Nodular regenerative hyperplasia (NRH) has been associated with didanosine use and can cause non-cirrhotic portal hypertension. Immune reconstitution inflammatory syndrome (IRIS) can unmask or worsen hepatitis B upon ART initiation. | Liver (hepatocytes, stellate cells, Kupffer cells); gut-associated lymphoid tissue (microbial translocation); metabolic system (lipodystrophy, insulin resistance); biliary system (AIDS cholangiopathy from CMV, Cryptosporidium); immune system | Evaluation includes comprehensive liver enzyme panel (ALT, AST, ALP, GGT, bilirubin), hepatitis B/C serology and viral load testing to exclude coinfection, imaging (ultrasound or CT) for steatosis and structural abnormalities, and non-invasive fibrosis assessment (FibroScan, FIB-4). HIV viral load and CD4 count contextualize the degree of immunosuppression. ART hepatotoxicity evaluation requires temporal correlation with drug initiation and drug-specific testing (lactic acid for NRTIs, HLA-B*5701 before abacavir). Liver biopsy may be needed for unexplained hepatitis and can reveal patterns suggesting specific etiologies (microvesicular steatosis for NRTI toxicity, granulomas for opportunistic infections, NRH for didanosine). Assessment for opportunistic hepatic infections (MAC, CMV, fungi) is important in patients with CD4 <200. | Management of HIV-associated hepatitis requires ART optimization: switch from hepatotoxic agents (didanosine, stavudine, nevirapine) to better-tolerated alternatives (tenofovir alafenamide, integrase inhibitors). For HIV/HBV coinfection, ART regimen must include tenofovir (TDF or TAF) plus emtricitabine or lamivudine as these agents have dual HIV/HBV activity. For HIV/HCV coinfection, DAA therapy achieves SVR in 95% with specific drug-drug interaction considerations (avoid certain protease inhibitors with some DAA combinations). NAFLD management includes lifestyle modifications (weight loss, exercise), treatment of metabolic comorbidities, and consideration of ART modifications to less metabolically disruptive agents. AIDS cholangiopathy is treated with ART initiation for immune reconstitution plus ERCP with sphincterotomy for symptomatic biliary obstruction. | Variable - The prognosis of HIV-associated liver disease depends on the specific etiology, degree of immunosuppression, and access to effective ART. With well-controlled HIV (undetectable viral load, CD4 >500), liver-related prognosis approaches that of HIV-negative individuals. However, liver disease remains the second leading cause of death in HIV-positive individuals on ART. Successful HCV treatment with DAAs dramatically improves liver-related outcomes in HIV/HCV coinfected patients. ART-related hepatotoxicity is generally reversible with drug substitution. Long-term, metabolic liver disease (NAFLD/NASH) is becoming the predominant liver concern in the aging HIV-positive population on ART, with fibrosis progression rates similar to or slightly higher than in the general population. | B20 |
| 11 | 10 | Hepatitis A | Viral Hepatitis | Hepatitis A virus (HAV) is a non-enveloped, single-stranded RNA picornavirus (genus Hepatovirus) transmitted primarily via the fecal-oral route through contaminated food, water, or close personal contact. HAV replicates in hepatocytes and is shed in bile and feces, reaching peak infectivity 1-2 weeks before symptom onset. The virus causes direct cytopathic injury and immune-mediated hepatocellular damage through CD8+ cytotoxic T-lymphocyte responses against infected hepatocytes. Unlike hepatitis B and C, HAV does not cause chronic infection, as robust innate and adaptive immune responses achieve complete viral clearance in virtually all immunocompetent individuals. | HAV infection affects approximately 1.4 million people annually worldwide according to WHO estimates, with highest endemicity in sub-Saharan Africa, South Asia, and Central America where seroprevalence exceeds 90% by age 10. In high-income countries, seroprevalence has declined dramatically due to improved sanitation and universal childhood vaccination, with incidence rates of 1-2 per 100,000. The introduction of the HAV vaccine in 1995 in the United States reduced incidence by over 95%. Outbreaks in developed countries now primarily affect people experiencing homelessness, injection drug users, and men who have sex with men. | In highly endemic regions, most infections occur in early childhood (under age 5) and are typically asymptomatic. In low-endemicity countries, infections increasingly occur in susceptible adolescents and adults who develop symptomatic illness. The mean age of infection has shifted upward in transitioning economies, paradoxically increasing disease severity at a population level. Symptomatic hepatitis A is rare in children under 6 years (less than 30% are symptomatic) but occurs in over 70% of infected adults. | The incubation period is 15-50 days (mean 28 days). Prodromal symptoms include fatigue, malaise, anorexia, nausea, vomiting, abdominal pain, and low-grade fever lasting 5-7 days. The icteric phase follows with jaundice, dark urine (bilirubinuria), pale stools (acholic), hepatomegaly, and pruritus lasting 2-8 weeks. Cholestatic hepatitis with prolonged jaundice exceeding 12 weeks occurs in approximately 5-10% of adults. Relapsing hepatitis with recurrent symptoms and transaminase elevations occurs in 3-20% of cases over 6-9 months but ultimately resolves completely. Fulminant hepatic failure is rare (0.015-0.5%) but risk increases with age and pre-existing liver disease. | Liver (hepatocytes primarily); biliary system; rarely kidneys (interstitial nephritis), joints (reactive arthritis), and hematologic system (aplastic anemia, hemolytic anemia in G6PD deficiency) | Diagnosis relies on detection of anti-HAV IgM antibodies in serum, which appear at symptom onset and remain detectable for 3-6 months, confirming acute infection. Anti-HAV IgG appears during convalescence and persists lifelong, indicating prior infection or vaccination and conferring immunity. Serum aminotransferases (ALT/AST) are markedly elevated, often exceeding 1000 IU/L, with ALT characteristically higher than AST. Total and direct bilirubin are elevated in icteric cases. HAV RNA detection by RT-PCR in serum or stool is used for epidemiologic studies and genotyping but is not required for routine diagnosis. Complete blood count may show relative lymphocytosis and mild thrombocytopenia. | Management is entirely supportive as no specific antiviral therapy exists. Treatment includes adequate hydration, rest, antiemetic agents for nausea, cholestyramine or ursodeoxycholic acid for pruritus in cholestatic cases, and avoidance of hepatotoxic agents including alcohol and acetaminophen. Hospitalization is required for patients with severe vomiting, dehydration, coagulopathy (INR >1.5), or signs of acute liver failure. Fulminant hepatic failure (approximately 0.5% of adult cases) requires referral for liver transplantation evaluation. Prevention is the primary strategy: HAV vaccine (2-dose inactivated vaccine series) is recommended for all children at age 1, travelers to endemic areas, persons with chronic liver disease, MSM, PWID, and persons experiencing homelessness per ACIP/AASLD guidelines. | Good - HAV infection is self-limiting with complete recovery in over 99% of cases. Fulminant hepatic failure occurs in less than 0.5% overall but increases to 1-2% in adults over 50 and those with underlying chronic liver disease, particularly chronic hepatitis C. There is no progression to chronic hepatitis, cirrhosis, or chronic carrier state. Mortality from fulminant HAV hepatitis is approximately 0.3-0.6% overall, with transplant-free survival of 50-60% in fulminant cases. Lifelong immunity develops after natural infection. Complete normalization of liver biochemistry occurs within 3-6 months in the vast majority of patients. | B15.9 |
| 12 | 11 | Hepatitis B with Delta Agent (HDV Coinfection) | Viral Hepatitis | Hepatitis D virus (HDV) is a defective, single-stranded circular RNA virus that requires the hepatitis B surface antigen (HBsAg) envelope for assembly, secretion, and de novo hepatocyte entry. HDV coinfection refers to simultaneous acquisition of HBV and HDV, typically through the same exposure event. HDV replicates autonomously within the hepatocyte nucleus using host RNA polymerase II, producing hepatitis D antigen (HDAg) in small (S-HDAg, promotes replication) and large (L-HDAg, promotes virion assembly) forms. The pathogenesis involves both direct cytotoxic effects of HDV replication and enhanced immune-mediated hepatocellular injury, resulting in more severe acute hepatitis compared to HBV monoinfection. | Globally, an estimated 12-72 million people are infected with HDV, with recent meta-analyses suggesting approximately 5% of HBsAg-positive individuals are anti-HDV positive. Highest prevalence is found in the Amazon Basin, Central Africa, Central Asia (Mongolia, where up to 60% of HBV carriers are HDV co-infected), the Middle East, the Mediterranean, and the Pacific Islands. In Western Europe and North America, HDV is primarily found among people who inject drugs and immigrants from endemic regions. Eight HDV genotypes have been identified, with genotype 1 being most widespread globally. | HDV coinfection can occur at any age but is most common in young adults through the same risk factors as HBV acquisition: injection drug use, sexual transmission, and percutaneous exposure. In endemic areas, coinfection may occur in childhood through household contact. Peak incidence mirrors that of acute HBV in the 20-40 age group in non-endemic settings. | Acute HBV/HDV coinfection typically presents as acute hepatitis that may be clinically indistinguishable from acute HBV monoinfection, though it tends to be more severe. A biphasic pattern of ALT elevation is characteristic, with the first peak from HBV and the second from HDV replication. Fulminant hepatic failure occurs in approximately 2-20% of coinfections, significantly higher than the 0.1-0.5% rate in acute HBV monoinfection. Symptoms include jaundice, fatigue, nausea, abdominal pain, dark urine, and in severe cases, coagulopathy and encephalopathy. | Liver (hepatocytes, with more extensive necrosis than HBV monoinfection); immune system; coagulation system in fulminant cases | Diagnosis requires detection of anti-HDV antibodies (total or IgM) in the setting of acute HBV infection (HBsAg-positive, anti-HBc IgM-positive). HDV RNA by RT-PCR confirms active HDV replication and is the most sensitive marker. Hepatitis D antigen (HDAg) can be detected in serum or liver tissue during early infection but is often transient. Simultaneous anti-HBc IgM positivity distinguishes coinfection from superinfection. ALT levels are typically markedly elevated (>10 times ULN), often with a biphasic pattern. HDV genotyping is available for epidemiologic purposes. | Treatment of acute HBV/HDV coinfection is primarily supportive, as most cases resolve spontaneously given that clearance of HBV leads to loss of HDV. Antiviral therapy with entecavir or tenofovir may be considered for severe cases with coagulopathy per AASLD guidance. Fulminant hepatic failure requires intensive care and liver transplantation evaluation. Bulevirtide (Hepcludex), an entry inhibitor targeting the NTCP receptor, is approved in Europe for chronic HDV but is not typically used in acute coinfection. Prevention of HBV through vaccination effectively prevents HDV coinfection, as HDV cannot infect without HBV. | Variable - Acute HBV/HDV coinfection is self-limiting in approximately 90-95% of cases, as HBV clearance eliminates the helper virus required for HDV persistence. However, fulminant hepatic failure occurs at a significantly higher rate (2-20%) compared to HBV monoinfection (0.1-0.5%), with mortality of 60-80% without transplantation. Chronicity develops in less than 5% of coinfection cases, similar to HBV monoinfection in adults. When chronic HDV infection does establish, it leads to the most severe form of chronic viral hepatitis with accelerated progression to cirrhosis. | B16.0 |
| 13 | 12 | Hepatitis B with Delta Agent (HDV Superinfection) | Viral Hepatitis | HDV superinfection occurs when a person with pre-existing chronic HBV infection acquires HDV, resulting in acute HDV hepatitis on a background of chronic HBV. Because HBsAg is already abundantly available in the chronically infected host, HDV can establish persistent infection much more readily than in coinfection. HDV superinfection suppresses HBV replication, often resulting in decreased HBV DNA and HBeAg levels, while HDV becomes the dominant driver of liver disease. This scenario represents the most severe form of chronic viral hepatitis, with accelerated progression to cirrhosis occurring in 70-80% of cases within 5-10 years. | HDV superinfection accounts for the majority of chronic HDV cases globally. Among the estimated 12-72 million people with HDV infection worldwide, most acquired it as superinfection of existing chronic HBV. The highest rates of superinfection are seen in injection drug users in endemic regions, with seroprevalence reaching 17-50% among HBV-positive PWID in some European cities. In the Amazon Basin, HDV superinfection can cause severe outbreaks of hepatitis among indigenous populations with high HBV carrier rates. | HDV superinfection can occur at any age in a chronic HBV carrier. In endemic areas, superinfection often occurs in childhood or young adulthood. In non-endemic settings, peak incidence is among young adults with injection drug use or other high-risk exposures. The risk is lifelong for any unvaccinated HBV carrier exposed to HDV. | HDV superinfection presents as either an acute exacerbation of previously stable chronic hepatitis B (severe acute hepatitis in a known HBV carrier) or as apparent new onset of hepatitis in a previously unrecognized HBV carrier. Symptoms include sudden onset jaundice, fatigue, nausea, right upper quadrant pain, dark urine, and in severe cases, ascites and coagulopathy indicating decompensation. ALT may rise to 10-100 times ULN. Fulminant hepatic failure occurs in approximately 5% of superinfection cases. If chronic HDV establishes, progressive liver disease with rapid fibrosis progression, recurrent hepatic flares, and early development of portal hypertension characterize the clinical course. | Liver (hepatocytes, with suppression of HBV and dominance of HDV-mediated injury); portal venous system (early portal hypertension); spleen (splenomegaly from portal hypertension) | Diagnosis requires demonstration of anti-HDV antibodies and/or HDV RNA in a patient with chronic HBV (HBsAg-positive for >6 months, anti-HBc IgM-negative or low-titer). Anti-HDV IgM indicates acute superinfection or active chronic HDV. HDV RNA by RT-PCR confirms active viral replication and is essential for treatment monitoring. The absence of anti-HBc IgM distinguishes superinfection from coinfection. HBV DNA is often suppressed to low or undetectable levels by HDV interference. Liver biopsy or non-invasive fibrosis assessment (FibroScan) is important for staging given the aggressive nature of chronic HDV. | Bulevirtide (Hepcludex) 2 mg subcutaneously daily is the first HDV-specific therapy, approved by EMA for chronic HDV with compensated liver disease, blocking HDV entry via NTCP receptor inhibition. Pegylated interferon alfa-2a (180 mcg weekly for at least 48 weeks, often extended to 96 weeks) has been the historical standard, achieving HDV RNA undetectability in 25-30% at end of treatment, though relapse rates are high (50%). Combination of bulevirtide plus pegylated interferon shows enhanced response rates in clinical trials (MYRB-301). Nucleos(t)ide analogues (entecavir, tenofovir) are indicated for HBV suppression, particularly if HBV DNA remains detectable, but have no direct activity against HDV. Liver transplantation is indicated for decompensated cirrhosis; HDV recurrence post-transplant is lower than HBV recurrence with appropriate HBIG/antiviral prophylaxis. | Poor - HDV superinfection leads to chronic HDV in approximately 80-90% of cases, making it the most common cause of chronic HDV. Chronic HDV is the most aggressive form of chronic viral hepatitis, with cirrhosis developing in 70-80% within 5-10 years and a 3-fold higher risk of HCC compared to HBV monoinfection. The annual rate of hepatic decompensation in HDV cirrhosis is approximately 4%, and 5-year survival after decompensation is only 50% without transplantation. Treatment with bulevirtide and/or pegylated interferon can slow disease progression in responders. Overall mortality from chronic HDV is 2-5 times higher than from HBV monoinfection. | B17.0 |
| 14 | 13 | Hepatitis D (Isolated Consideration) | Viral Hepatitis | Hepatitis D virus (HDV) is a satellite virus and the smallest known human pathogen, with a 1.7 kb single-stranded circular RNA genome encoding only one protein (hepatitis D antigen) and requiring HBV-derived HBsAg for virion assembly and hepatocyte entry via the NTCP receptor. HDV possesses ribozyme activity and replicates through a double rolling-circle mechanism using host RNA polymerase II redirected to an RNA template, a unique feature among animal viruses. Eight genotypes are recognized: genotype 1 (worldwide, most common), genotype 2 (East Asia), genotype 3 (Amazon Basin, associated with severe hepatitis and high mortality), and genotypes 4-8 (Africa). The pathogenesis involves both direct cytopathic effects (particularly genotype 3) and immune-mediated hepatocellular injury, making HDV the most pathogenic of all hepatitis viruses. | Global HDV prevalence estimates have varied widely, with recent meta-analyses suggesting 12-72 million people infected (approximately 5% of HBsAg-positive individuals globally). The highest endemicity is found in the Amazon Basin (genotype 3, prevalence up to 40% among indigenous HBV carriers), Mongolia (genotype 1, up to 60% of HBV carriers), Central African Republic, Romania, and parts of Central Asia. In Western Europe and North America, HDV is primarily found among immigrants from endemic countries and people who inject drugs. Global prevalence may be increasing in some regions due to migration patterns and persistent injection drug use. | HDV acquisition mirrors HBV transmission routes and can occur at any age. In endemic areas (Amazon Basin, Central Africa, Central Asia), HDV is frequently acquired in childhood through horizontal transmission among HBV carriers. In non-endemic countries, infection predominantly occurs in young adults through injection drug use or sexual transmission. HDV genotype 3 infection in the Amazon Basin can affect children and young adults with devastating fulminant hepatitis (Labrea hepatitis). | Clinical manifestations depend on whether HDV is acquired as coinfection (with acute HBV) or superinfection (on chronic HBV). Superinfection, the more common scenario, presents as an acute hepatitis flare in a chronic HBV carrier, often severe, progressing to chronic HDV in 80-90% of cases. Chronic HDV causes accelerated liver fibrosis with cirrhosis developing in 70-80% within 5-10 years. Genotype 3 HDV in the Amazon Basin causes a uniquely severe form of hepatitis (Labrea fever/hepatitis) with microvesicular steatosis, morula cells, and high mortality. Portal hypertension develops early in the disease course, and HCC risk is 3-6 times higher than in HBV monoinfection. | Liver (hepatocytes, with more severe necroinflammation than any other viral hepatitis); portal venous system (early portal hypertension); spleen (congestive splenomegaly) | Screening for HDV should be performed in all HBsAg-positive patients per AASLD and EASL guidelines using anti-HDV total antibody testing. If anti-HDV is positive, HDV RNA by quantitative RT-PCR confirms active infection and is essential for treatment monitoring. Anti-HDV IgM suggests active replication and is used as a surrogate where HDV RNA testing is unavailable. Quantitative HBsAg levels correlate with HDV activity and treatment response. HDV genotyping is available but not routine in clinical practice. Liver fibrosis assessment by FibroScan or liver biopsy is essential given the aggressive disease course. | Bulevirtide (Hepcludex) 2 mg subcutaneously daily is the first approved HDV-specific therapy (EMA 2020), blocking viral entry through NTCP receptor inhibition. Pegylated interferon alfa-2a 180 mcg weekly for 48-96 weeks achieves HDV RNA undetectability in 25-30% at end of treatment but has high relapse rates and significant side effects. Combination of bulevirtide plus pegylated interferon shows superior response rates. Lonafarnib (a prenylation inhibitor preventing L-HDAg modification) is in advanced clinical trials. Nucleos(t)ide analogues suppress HBV but have no direct anti-HDV activity. Liver transplantation is indicated for decompensated cirrhosis; post-transplant outcomes are favorable with low HDV recurrence rates using HBIG plus nucleos(t)ide analogue prophylaxis. | Poor - Chronic HDV causes the most severe form of chronic viral hepatitis, with cirrhosis developing in 70-80% of patients within 5-10 years, compared to 20-30% over 20-30 years for HBV monoinfection. The risk of hepatic decompensation is 3-4 times higher and HCC risk is 3-6 times higher than in HBV monoinfection. Five-year survival after hepatic decompensation is approximately 50% without transplantation. Genotype 3 HDV causes an especially severe and rapidly progressive disease (Labrea hepatitis) with high acute mortality. With bulevirtide therapy, HDV RNA decline and ALT normalization occur in 45-70% of patients, offering hope for improved outcomes. Liver transplantation offers excellent results with 5-year graft survival exceeding 85%. | B17.0 |
| 15 | 14 | Hepatitis E | Viral Hepatitis | Hepatitis E virus (HEV) is a non-enveloped (in bile/feces) or quasi-enveloped (in blood) single-stranded positive-sense RNA virus in the family Hepeviridae. Genotypes 1 and 2 are obligate human pathogens transmitted fecal-orally through contaminated water, causing large waterborne outbreaks in developing countries. Genotypes 3 and 4 are zoonotic viruses transmitted from animal reservoirs (primarily pigs, deer, wild boar) to humans through consumption of undercooked meat, particularly pork, and can cause sporadic infections in developed countries. HEV replicates in hepatocytes and is shed in bile; liver injury is primarily immune-mediated through cytotoxic T-cell responses and interferon-gamma production. | HEV is the most common cause of acute viral hepatitis worldwide, with an estimated 20 million infections and 3.3 million symptomatic cases annually, resulting in approximately 44,000 deaths (WHO). Genotypes 1/2 are endemic in South and Southeast Asia, sub-Saharan Africa, and Central America, where large waterborne outbreaks affect thousands. Genotypes 3/4 are found in developed countries (Europe, North America, Japan) as sporadic zoonotic infections, with increasing recognition due to improved testing. Anti-HEV IgG seroprevalence is surprisingly high even in developed countries (5-25% in Europe, USA), reflecting frequent subclinical exposure. | Genotype 1/2 HEV predominantly affects young adults aged 15-40 years in endemic regions, with epidemics having the highest attack rates in this age group. Genotype 3/4 infections in developed countries predominantly affect middle-aged and older men (median age 50-65 years), particularly those consuming raw/undercooked pork or game meat. Pregnant women are uniquely susceptible to severe genotype 1 infection. Children are often infected but typically asymptomatic in endemic areas. | The incubation period is 15-60 days (mean 40 days). Most infections are self-limiting with symptoms similar to other acute viral hepatitis: jaundice, fatigue, nausea, anorexia, abdominal pain, dark urine, and hepatomegaly. Anicteric infection is common, especially in children and with genotype 3/4. Neurological manifestations (Guillain-Barre syndrome, neuralgic amyotrophy, Bell's palsy, transverse myelitis) are increasingly recognized, particularly with genotype 3. Renal manifestations include membranoproliferative glomerulonephritis and cryoglobulinemia. Pancreatitis and hematologic disorders (thrombocytopenia, aplastic anemia) may occur. | Liver (hepatocytes); nervous system (peripheral nerves, brachial plexus); kidneys (glomerulonephritis); pancreas; hematologic system; fetus (in pregnant women, vertical transmission) | Diagnosis of acute HEV relies on detection of anti-HEV IgM antibodies (sensitivity 95-100% for genotypes 1/2, lower for genotype 3/4 in immunocompromised patients). HEV RNA detection by RT-PCR in serum or stool is more sensitive and essential for diagnosing chronic HEV in immunocompromised patients where antibody responses may be blunted. Anti-HEV IgG indicates past exposure but may also be positive in acute infection. ALT elevation is typically 10-20 times ULN. HEV genotyping is performed on RNA-positive samples for epidemiologic and clinical purposes (genotype 3/4 can chronify in immunosuppressed). Anti-HEV assays vary significantly in sensitivity/specificity between manufacturers. | Acute HEV in immunocompetent individuals is self-limiting and requires only supportive care. In immunocompromised patients with chronic HEV (genotype 3/4), reduction of immunosuppressive therapy (particularly tacrolimus, by 25-50%) achieves viral clearance in 30% of cases and should be attempted first. If immunosuppression reduction fails, ribavirin monotherapy (600-800 mg daily for 12 weeks, with extension if needed) achieves sustained virologic response in 80-85% of chronic HEV cases per EASL guidelines. Pegylated interferon alfa-2a can be used as second-line in non-transplant patients. A recombinant HEV vaccine (Hecolin, HEV 239) is licensed only in China and shows 95% efficacy against genotype 4. Pregnant women with severe hepatitis E require intensive supportive care; early delivery may be considered in the third trimester. | Good - Acute HEV in immunocompetent non-pregnant adults is self-limiting with complete recovery in over 95% of cases. Case fatality rate is 0.5-4% in the general population but rises to 20-25% in pregnant women with genotype 1 infection, representing the highest mortality of any acute viral hepatitis in this population. Fulminant hepatic failure occurs in 0.5-4% overall. Chronic HEV occurs exclusively in immunocompromised individuals (organ transplant recipients, HIV/AIDS, hematologic malignancies) infected with genotypes 3 or 4, progressing to cirrhosis in 10% within 2 years if untreated. With ribavirin therapy, cure rates for chronic HEV exceed 80%. | B17.2 |
| 16 | 15 | Hepatitis E in Pregnancy | Viral Hepatitis | HEV genotype 1 (and to a lesser extent genotype 2) causes disproportionately severe hepatitis during pregnancy, particularly in the second and third trimesters, through mechanisms that remain incompletely understood. Proposed explanations include pregnancy-associated immune modulation (shift toward Th2 immunity, reduced Th1 responses needed for viral clearance), hormonal effects (elevated estrogen and progesterone altering immune function and hepatocyte susceptibility), and placental tropism of HEV genotype 1 (with viral replication in placental trophoblasts causing placental injury and vertical transmission). The high progesterone levels in pregnancy upregulate HEV replication through nuclear factor NF-kB pathway modulation. Notably, genotypes 3 and 4 do NOT cause increased severity in pregnancy, suggesting genotype-specific virulence factors. | Hepatitis E in pregnancy is a major public health problem in endemic regions (South Asia, sub-Saharan Africa, Central America). In India, HEV accounts for 60% of acute viral hepatitis during pregnancy, with outbreaks causing disproportionate mortality among pregnant women. Case fatality rates reach 20-25% during pregnancy, compared to 0.5-4% in non-pregnant adults, making it the deadliest form of acute viral hepatitis in this population. During the Sar-e-Pol outbreak in Afghanistan (2003-2004), the mortality rate among pregnant women with HEV was 22%. | The risk of severe HEV is highest during the second and third trimesters of pregnancy, with fulminant hepatic failure most common at 28-38 weeks gestation. First trimester infections tend to have outcomes similar to non-pregnant women. Women of reproductive age (15-45 years) in endemic areas are the primary at-risk population. The severity is specific to genotype 1/2 infections and does not apply to genotype 3/4 infections in developed countries. | Presentation ranges from acute icteric hepatitis to fulminant hepatic failure with encephalopathy and disseminated intravascular coagulation (DIC). Fulminant hepatic failure develops in 15-25% of pregnant women infected in the third trimester, characterized by rapid onset jaundice, coagulopathy, hepatic encephalopathy, and multiorgan failure. Obstetric complications include intrauterine fetal death (33%), preterm delivery, stillbirth, and neonatal hepatitis from vertical transmission (33-50% of neonates born to viremic mothers). DIC is a particularly common and life-threatening complication. Acute pancreatitis may accompany hepatic failure. | Liver (hepatocytes, with massive necrosis in fulminant cases); placenta (trophoblast infection, placental inflammation); fetus (vertical transmission, neonatal hepatitis); coagulation system (DIC); kidneys (hepatorenal syndrome, acute tubular necrosis); brain (hepatic encephalopathy) | Diagnosis follows the same approach as non-pregnant HEV: anti-HEV IgM and HEV RNA by RT-PCR. Important to distinguish from other causes of acute liver failure in pregnancy: HELLP syndrome (hemolysis, elevated liver enzymes, low platelets), acute fatty liver of pregnancy (AFLP), pre-eclampsia/eclampsia, and herpes simplex hepatitis. ALT levels are typically markedly elevated (>1000 IU/L). Coagulation studies (PT/INR, fibrinogen, D-dimer) are essential to detect DIC. Fetal monitoring with ultrasound and cardiotocography is critical. Ammonia levels and blood glucose monitoring are needed in encephalopathic patients. | Management is primarily supportive with intensive care for severe cases. No antiviral therapy has been proven safe and effective in pregnancy; ribavirin is absolutely contraindicated (Category X teratogen). Intensive supportive care includes aggressive fluid management, correction of coagulopathy (fresh frozen plasma, cryoprecipitate, vitamin K), management of hepatic encephalopathy (lactulose, rifaximin), nutritional support, and renal replacement therapy if needed. Early delivery (induction or cesarean) should be considered in the third trimester when maternal condition deteriorates, as delivery often improves hepatic function. Liver transplantation may be life-saving in fulminant cases, though decision-making is complex given fetal considerations. Prevention through improved sanitation and water quality in endemic areas is paramount. | Poor - Mortality from HEV in pregnancy reaches 20-25% (compared to 0.5-4% in non-pregnant adults), making it the most lethal presentation of acute viral hepatitis. Fulminant hepatic failure occurs in 15-25% of third-trimester infections. Fetal mortality is approximately 33%, with high rates of preterm delivery, stillbirth, and neonatal hepatitis. Vertical transmission occurs in 33-50% of neonates born to viremic mothers, with neonatal HEV hepatitis carrying its own mortality risk. Among survivors, complete hepatic recovery is expected as chronic HEV does not develop with genotype 1/2 in immunocompetent individuals. Maternal survival with intensive care has improved in tertiary centers but remains poor in resource-limited settings where the disease burden is greatest. | B17.2 |
| 17 | 16 | Herpes Simplex Virus (HSV) Hepatitis | Viral Hepatitis | Herpes simplex virus hepatitis is a rare but frequently fatal form of viral hepatitis caused by HSV-1 or HSV-2 dissemination to the liver. It occurs almost exclusively in immunocompromised patients (organ transplant recipients, patients on chemotherapy or high-dose corticosteroids, HIV/AIDS), neonates, pregnant women (particularly third trimester), and occasionally in apparently immunocompetent individuals with no identifiable risk factors. HSV directly infects hepatocytes, causing widespread coagulative hepatocellular necrosis with characteristic intranuclear inclusions (Cowdry type A bodies, ground-glass nuclei, and nuclear molding). The hallmark of HSV hepatitis is anicteric hepatic failure: markedly elevated transaminases (often >5000 IU/L) with coagulopathy but minimal jaundice, a pattern that distinguishes it from most other causes of acute liver failure. | HSV hepatitis is rare, accounting for approximately 1-2% of all cases of acute liver failure in published series. It is the most common fatal herpesvirus infection in organ transplant recipients. The true incidence is likely underestimated because diagnosis is frequently made post-mortem. Pregnant women, especially in the third trimester, represent a high-risk group even among immunocompetent women. The mortality rate exceeds 70% without early antiviral therapy and remains approximately 50% even with treatment due to diagnostic delays. | HSV hepatitis can occur at any age in susceptible populations. Neonatal HSV hepatitis occurs in the first 2 weeks of life as part of disseminated neonatal herpes, most commonly acquired during vaginal delivery from a mother with active genital HSV. In adults, it most commonly affects immunosuppressed patients aged 30-60 years and pregnant women in the third trimester. Immunocompetent adults with HSV hepatitis have a median age of approximately 35 years. | HSV hepatitis presents with high fever, malaise, and rapidly progressive hepatic failure over days. The cardinal feature is markedly elevated aminotransferases (often 5,000-10,000+ IU/L) with relatively preserved bilirubin (anicteric hepatitis), distinguishing it from most other hepatitis etiologies. Coagulopathy develops rapidly, with INR often exceeding 2-3. Mucocutaneous herpetic lesions are present in only 30-50% of cases, making clinical diagnosis challenging. Leukopenia and thrombocytopenia from HSV-induced bone marrow suppression are common. DIC may develop. Without treatment, rapid progression to multiorgan failure and death occurs within days. | Liver (hepatocytes, with extensive coagulative necrosis); adrenal glands (adrenal hemorrhagic necrosis); skin/mucosa (vesicles when present); bone marrow (myelosuppression); lungs (pneumonitis); CNS (encephalitis); coagulation system (DIC) | High clinical suspicion is essential, as diagnosis is often delayed or missed. HSV PCR from blood (viremia) is the most sensitive and rapid diagnostic test. Liver biopsy showing geographic/coalescent areas of coagulative necrosis with intranuclear Cowdry type A inclusions, ground-glass nuclei, and multinucleated hepatocytes is diagnostic. Immunohistochemistry for HSV-1/HSV-2 antigens on biopsy confirms the diagnosis. The classic laboratory profile (extremely high AST/ALT >5000 IU/L with near-normal bilirubin) should prompt immediate consideration of HSV hepatitis. Mucocutaneous swabs for HSV culture/PCR should be obtained if lesions are present but their absence does not exclude the diagnosis. | Intravenous acyclovir (10 mg/kg every 8 hours, adjusted for renal function) must be initiated immediately upon clinical suspicion, before confirmatory test results, as delay in treatment dramatically increases mortality. Treatment duration is typically 14-21 days, with transition to oral valacyclovir for suppressive therapy in immunocompromised patients. Liver transplantation has been performed for HSV-associated acute liver failure with variable results, as systemic HSV disease may recur in the graft. Supportive care includes management of coagulopathy, DIC, and multiorgan dysfunction in an intensive care setting. Prevention in high-risk transplant recipients includes acyclovir/valacyclovir prophylaxis. | Poor - HSV hepatitis carries a mortality rate exceeding 70-80% without antiviral treatment and approximately 50% even with early acyclovir therapy, making it one of the most lethal forms of viral hepatitis. Early recognition and treatment initiation are the most important prognostic factors: mortality drops to 30% when acyclovir is started before onset of hepatic failure. Neonatal disseminated HSV hepatitis carries a mortality of 30% even with treatment. Survivors generally recover liver function completely if treated early enough. The diagnosis is frequently made post-mortem (up to 50% of cases in some series), highlighting the need for heightened clinical awareness. | B00.81 |
| 18 | 17 | Yellow Fever Hepatitis | Viral Hepatitis | Yellow fever is caused by the Yellow Fever virus (YFV), a single-stranded RNA flavivirus transmitted by Aedes aegypti mosquitoes (urban cycle) and Haemagogus/Sabethes species (sylvatic cycle). The liver is the primary target organ, with YFV showing strong hepatotropism and causing characteristic midzonal hepatocellular necrosis (zone 2 of the hepatic acinus), a distinctive pattern that spares periportal and pericentral hepatocytes. Hepatocellular injury involves both direct viral cytopathic effects and apoptosis (marked by Councilman bodies, eosinophilic rounded apoptotic hepatocytes that are the histologic hallmark of yellow fever). The disease progresses through three phases: infection (viremia), remission, and intoxication (hepatorenal failure with jaundice), with approximately 15-25% of symptomatic patients progressing to the severe toxic phase. | Yellow fever is endemic in tropical and subtropical regions of Africa and South America, affecting 47 countries with a combined at-risk population of approximately 900 million people. WHO estimates 200,000 cases and 30,000 deaths annually, with 90% occurring in Africa. Major urban outbreaks have occurred in Angola-DRC (2016) and Brazil (2017-2018). Yellow fever has never been reported in Asia despite the presence of competent Aedes aegypti vectors. An effective live-attenuated vaccine (YF-17D) is available and provides lifelong immunity after a single dose, but coverage gaps in endemic areas perpetuate transmission. | Yellow fever affects all age groups in endemic areas. In Africa, children under 15 are most commonly affected, particularly in areas with low vaccine coverage. In South America, adult males involved in forestry, agriculture, or tourism in jungle areas are at highest risk (sylvatic cycle). Unvaccinated travelers to endemic areas are at risk regardless of age. Infants under 6 months and adults over 60 years have an increased risk of severe disease and vaccine-associated viscerotropic disease. | After a 3-6 day incubation, the infection phase presents with sudden onset high fever, headache, myalgia, nausea, and viremia lasting 3-4 days. A brief remission of hours to a day follows. Approximately 15-25% of patients then enter the toxic phase (intoxication), characterized by the classic triad of jaundice (giving the disease its name), hemorrhage (hematemesis/vomito negro, epistaxis, melena, petechiae), and renal failure (albuminuria progressing to oliguria/anuria). Hepatic failure manifests with markedly elevated transaminases (AST>ALT is characteristic, unlike most other hepatitides, due to myocardial involvement), coagulopathy, and encephalopathy. Faget's sign (bradycardia relative to fever) is a classic clinical finding. | Liver (hepatocytes with midzonal necrosis); kidneys (acute tubular necrosis); heart (myocarditis); blood vessels (endothelial injury, hemorrhage); bone marrow (myelosuppression); brain (encephalopathy, cerebral edema) | Diagnosis is based on clinical presentation in an epidemiologic context (endemic area, no vaccination history). Yellow fever IgM by ELISA appears 3-5 days after symptom onset but cross-reacts with other flaviviruses (dengue, Zika, West Nile), requiring confirmatory plaque reduction neutralization testing (PRNT). YFV RNA by RT-PCR is positive during the viremic phase (first 5-7 days). Four-fold rise in IgG titers between acute and convalescent sera is confirmatory. Liver biopsy (usually post-mortem) shows characteristic midzonal necrosis with Councilman bodies, fatty change, and absence of significant inflammatory infiltrate. Transaminases are markedly elevated with AST characteristically higher than ALT. Leukopenia and thrombocytopenia are typical. | No specific antiviral therapy exists for yellow fever. Management is entirely supportive and includes intensive care for severe cases with fluid resuscitation, vasopressor support, management of coagulopathy (fresh frozen plasma, vitamin K, platelet transfusion), renal replacement therapy for acute kidney injury, and management of hepatic failure (lactulose, protein restriction). Aspirin and NSAIDs are contraindicated due to hemorrhagic risk. Liver transplantation has been reported in rare cases but evidence is limited. Prevention through vaccination is paramount: the live-attenuated YF-17D vaccine is highly effective (99% seroconversion), provides lifelong immunity after a single dose per WHO, and is required for entry into endemic countries. Mosquito control measures (elimination of breeding sites, insecticide spraying) complement vaccination. | Variable - Overall case fatality rate among symptomatic yellow fever cases is approximately 20-50% during the toxic phase, with higher mortality in unvaccinated individuals, children, and the elderly. Among patients who develop the full toxic phase with hepatorenal failure, mortality reaches 50-80%. Patients who survive the toxic phase generally recover completely without chronic liver disease. Among all infected individuals (including subclinical infections), the case fatality rate is 3-7.5%. The yellow fever vaccine is one of the most effective vaccines available, with a single dose providing lifelong protection in 99% of recipients. Vaccine-associated viscerotropic disease (essentially wild-type yellow fever from the vaccine strain) is extremely rare (0.3-0.4 per 100,000 doses) but has a case fatality rate of approximately 60%. | A95.9 |
| 19 | ▸ Alcoholic Liver Disease | |||||||||||
| 20 | 18 | Alcohol-Associated Steatohepatitis (ASH) | Alcoholic Liver Disease | Alcohol-associated steatohepatitis (ASH) is the inflammatory phase of ALD characterized by hepatocyte injury (ballooning degeneration), lobular inflammation (predominantly neutrophilic), and steatosis, with or without Mallory-Denk bodies and fibrosis. ASH represents a transition point in ALD where immune-mediated injury amplifies direct alcohol toxicity. The pathogenesis involves gut-liver axis dysregulation: alcohol increases intestinal permeability, allowing translocation of bacterial endotoxin (LPS) to the portal circulation, activating Kupffer cells via TLR4 to produce pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-8). Recruited neutrophils infiltrate the liver parenchyma, surrounding damaged hepatocytes (satellitosis), and cause further injury through oxidative burst. ASH can be clinically silent or present as acute alcoholic hepatitis. | ASH develops in approximately 10-35% of heavy drinkers, intermediate between simple steatosis (90% prevalence) and cirrhosis (10-20%). Histologically documented ASH is found in approximately 20% of heavy drinkers who undergo liver biopsy. The condition may be present subclinically for years before clinical recognition. Risk factors for developing ASH include female sex, obesity, binge drinking pattern, and genetic susceptibility (PNPLA3 I148M). | ASH can develop at any point during the course of heavy alcohol use, typically after 5-15 years of heavy drinking. Most commonly diagnosed in adults aged 35-55 years. Women develop ASH at lower alcohol intake (20-40g/day) compared to men (40-80g/day). | ASH may be subclinical (detected only on biopsy) or present with symptoms ranging from mild (fatigue, malaise, mild right upper quadrant discomfort) to severe acute alcoholic hepatitis (jaundice, fever, coagulopathy, encephalopathy). Hepatomegaly is common. Laboratory findings include elevated AST (typically <300 IU/L) with AST/ALT ratio >1.5-2.0, elevated GGT, elevated bilirubin (in symptomatic cases), leukocytosis with neutrophilia, and elevated MCV. The severity spectrum ranges from mild subclinical inflammation to life-threatening alcoholic hepatitis. | Liver (hepatocytes with ballooning, steatosis, lobular neutrophilic inflammation, Mallory-Denk bodies); gut-liver axis (increased intestinal permeability, endotoxemia); immune system (Kupffer cell activation, neutrophil recruitment) | Definitive diagnosis requires liver biopsy showing the characteristic triad of hepatocyte ballooning, lobular inflammation (predominantly neutrophilic), and steatosis. The NAFLD Activity Score (NAS) adapted for ALD or the Alcoholic Hepatitis Histologic Score can grade severity. Non-invasive diagnosis is based on clinical-laboratory criteria (heavy alcohol use, AST/ALT pattern, elevated GGT) after excluding other etiologies. Transient elastography may overestimate fibrosis during active inflammation. Scoring systems (MDF, MELD, Lille, GAHS) assess severity in acute presentations. | Alcohol abstinence is the foundation of management for all severities. For subclinical or mild ASH: abstinence, nutritional support, and monitoring. For severe ASH (clinical alcoholic hepatitis with MDF >=32): prednisolone 40mg/day for 28 days if no contraindications, with Lille score assessment at day 7. Pentoxifylline is no longer recommended. Nutritional support with 35-40 kcal/kg/day and 1.2-1.5 g/kg/day protein. Early liver transplantation for select non-responders to medical therapy. Treatment of alcohol use disorder with behavioral interventions and pharmacotherapy. | Variable - Subclinical ASH has a favorable prognosis with abstinence, with resolution of inflammation and potential regression of early fibrosis. Clinical alcoholic hepatitis (severe ASH) has 28-day mortality of 30-50% without treatment. Long-term, the presence of histologic ASH (even subclinical) is the strongest predictor of progression to cirrhosis: 40-50% develop cirrhosis within 5-10 years with continued drinking. Abstinence at any stage reduces mortality and can lead to improvement or stabilization of liver disease. | K70.10 |
| 21 | 19 | Alcohol-Related Hepatocellular Carcinoma | Alcoholic Liver Disease | Hepatocellular carcinoma (HCC) in the setting of alcohol-related liver disease develops through multiple oncogenic pathways driven by chronic alcohol exposure. Ethanol and acetaldehyde are direct carcinogens that promote DNA damage through oxidative stress (reactive oxygen species from CYP2E1 induction), acetaldehyde-DNA adduct formation, epigenetic modifications (DNA methylation alterations), and impaired DNA repair mechanisms. The chronic inflammatory milieu of alcoholic liver disease promotes hepatocyte proliferation, telomere shortening, and genomic instability. Alcohol synergizes with other risk factors: HBV/HCV coinfection, diabetes, obesity, and iron overload multiply HCC risk in drinkers. | Alcohol accounts for approximately 30% of HCC cases in Western countries and 15-20% globally. The annual incidence of HCC in alcoholic cirrhosis is 1-3%, lower than in HCV or HBV cirrhosis but significant given the large population at risk. Risk is dose-dependent, with >80g/day conferring a 5-fold increased HCC risk. Notably, heavy alcohol use increases HCC risk even in the absence of cirrhosis, though the risk is much higher with established cirrhosis. | HCC in alcoholic liver disease typically develops after age 50-60, usually in the setting of established cirrhosis that has been present for years. Males are affected more frequently (3-4:1 ratio). The latency from the onset of heavy drinking to HCC development is typically 20-30 years through the pathway of steatosis, steatohepatitis, fibrosis, cirrhosis, and then HCC. | HCC is often detected during routine surveillance (ultrasound every 6 months) in patients with known cirrhosis. When symptomatic, patients present with right upper quadrant pain, palpable hepatic mass, weight loss, worsening ascites, or hepatic decompensation. Paraneoplastic syndromes include erythrocytosis, hypercalcemia, hypoglycemia, and watery diarrhea. Alpha-fetoprotein (AFP) elevation >400 ng/mL is highly suggestive but is elevated in only 40-60% of HCC cases. | Liver (hepatocellular carcinoma arising in cirrhotic parenchyma); portal venous system (tumor thrombus in portal vein); lungs (metastasis); bones (metastasis); adrenal glands (metastasis); peritoneum (metastasis) | HCC surveillance in alcoholic cirrhosis: abdominal ultrasound with or without AFP every 6 months per AASLD guidelines. Suspicious lesions are evaluated with multiphase contrast-enhanced CT or MRI: arterial phase hyperenhancement with portal venous/delayed phase washout is the hallmark of HCC (LI-RADS 5). Biopsy is reserved for atypical imaging findings. Staging uses the Barcelona Clinic Liver Cancer (BCLC) system. AFP, AFP-L3 fraction, and des-gamma-carboxy prothrombin (DCP) serve as tumor biomarkers. Liver function assessment (Child-Pugh, MELD) is essential for treatment planning. | Treatment follows BCLC staging: very early/early stage (BCLC 0/A): surgical resection, liver transplantation (within Milan criteria: single tumor <=5cm or up to 3 tumors <=3cm each), or ablation (radiofrequency or microwave). Intermediate stage (BCLC B): transarterial chemoembolization (TACE). Advanced stage (BCLC C): systemic therapy with atezolizumab plus bevacizumab (first-line per IMbrave150 trial), or sorafenib/lenvatinib if immunotherapy is contraindicated. Terminal stage (BCLC D): best supportive care. Alcohol abstinence remains important for optimizing liver function reserve and treatment eligibility. Liver transplantation uniquely treats both HCC and underlying cirrhosis. | Variable - Prognosis depends on tumor stage, liver function, and treatment received. Very early HCC (BCLC 0): 5-year survival 70-80% with resection or transplantation. Early HCC (BCLC A): 5-year survival 50-70% with curative treatments. Intermediate HCC (BCLC B): median survival 20-26 months with TACE. Advanced HCC (BCLC C): median survival 12-19 months with atezolizumab/bevacizumab. Alcohol-related HCC has similar stage-for-stage survival compared to viral hepatitis-related HCC. Prevention through abstinence, cirrhosis management, and regular surveillance offers the best chance for early detection and curative treatment. | C22.0 |
| 22 | 20 | Alcoholic Cirrhosis | Alcoholic Liver Disease | Alcoholic cirrhosis represents the end stage of progressive alcohol-related liver injury, characterized by diffuse hepatic fibrosis with regenerative nodule formation, architectural distortion, and vascular remodeling leading to portal hypertension. The pathogenesis involves decades of alcohol-mediated hepatocyte injury, stellate cell activation, and collagen deposition, culminating in complete disruption of the normal hepatic lobular architecture. Micronodular cirrhosis (<3mm nodules) is the typical initial pattern in ALD, which may evolve to macronodular or mixed pattern after abstinence. Portal hypertension develops from increased intrahepatic vascular resistance (structural and functional via reduced nitric oxide bioavailability) and splanchnic vasodilation, driving the complications of ascites, variceal hemorrhage, and hepatorenal syndrome. | Alcoholic cirrhosis is the most common cause of cirrhosis worldwide and in Western countries, accounting for approximately 50% of all cirrhosis-related deaths. In the US, approximately 44,000 deaths annually are attributed to alcohol-associated liver disease. Globally, alcohol-related cirrhosis accounts for approximately 25% of all cirrhosis cases. The prevalence has been increasing, particularly since the COVID-19 pandemic, with a documented surge in alcohol consumption and alcohol-related liver disease presentations. | Alcoholic cirrhosis typically develops after 20-30 years of heavy drinking, with median age at diagnosis of 50-60 years. However, accelerated progression can occur in women, individuals with genetic susceptibility (PNPLA3, TM6SF2), those with concurrent viral hepatitis, and obese individuals. Decompensation may be the first clinical presentation, as many patients are asymptomatic during the compensated phase. | Compensated cirrhosis may be asymptomatic or present with fatigue, anorexia, weight loss, and muscle wasting. Physical findings include spider angiomata, palmar erythema, gynecomastia, testicular atrophy, Dupuytren's contracture, parotid gland enlargement, and caput medusae. Decompensated cirrhosis manifests with ascites (most common decompensating event), variceal hemorrhage, hepatic encephalopathy (confusion, asterixis, somnolence), and jaundice. Hepatorenal syndrome (progressive renal failure in the setting of cirrhosis) carries a very poor prognosis. Spontaneous bacterial peritonitis (SBP) occurs in 10-30% of patients with ascites. | Liver (diffuse fibrosis, regenerative nodules, portal hypertension); portal venous system (varices, portal hypertensive gastropathy); spleen (congestive splenomegaly); kidneys (hepatorenal syndrome); brain (hepatic encephalopathy); lungs (hepatopulmonary syndrome, portopulmonary hypertension); cardiovascular system (cirrhotic cardiomyopathy); endocrine system (hypogonadism); hematologic system (pancytopenia from hypersplenism, coagulopathy) | Diagnosis is often clinical in the appropriate context (long-standing heavy alcohol use plus signs of chronic liver disease and portal hypertension). FibroScan values >12.5 kPa suggest cirrhosis. Imaging (ultrasound, CT, MRI) shows nodular liver contour, splenomegaly, ascites, and portosystemic collaterals. Upper endoscopy screens for esophageal and gastric varices. MELD score (based on bilirubin, INR, creatinine) assesses disease severity and guides transplant listing priority. Child-Pugh classification (A, B, C) based on bilirubin, albumin, INR, ascites, and encephalopathy grades severity. HCC surveillance with ultrasound every 6 months is mandatory. Liver biopsy confirms diagnosis when uncertain. | Alcohol abstinence remains the most important intervention at any stage of cirrhosis and significantly improves survival. Compensated cirrhosis: HCC surveillance, variceal screening, bone density assessment, nutritional optimization (35 kcal/kg/day, 1.2-1.5 g/kg/day protein). Decompensated cirrhosis: ascites management (sodium restriction 2g/day, spironolactone 100-400mg + furosemide 40-160mg, paracentesis with albumin), variceal bleeding prophylaxis/treatment (non-selective beta-blockers, band ligation), hepatic encephalopathy treatment (lactulose, rifaximin 550mg BID), SBP prophylaxis (norfloxacin). Liver transplantation is the definitive treatment for decompensated disease, with excellent post-transplant survival (75-80% at 5 years); most programs require 6 months of documented abstinence, though this is evolving. | Poor - Compensated alcoholic cirrhosis has a 10-year survival of approximately 50% with continued drinking and 70-80% with abstinence. Once decompensation occurs, median survival without transplantation is approximately 2-4 years. Abstinence improves survival at every stage: 5-year survival in compensated cirrhosis improves from 35% (continued drinking) to 60% (abstinent). HCC develops at a rate of 1-3% per year in alcoholic cirrhosis. Liver transplantation achieves 75-80% 5-year survival, with alcohol relapse rates of 10-30% post-transplant (though most relapses are not harmful drinking). MELD score is the best predictor of short-term mortality without transplantation. | K70.30 |
| 23 | 21 | Alcoholic Fatty Liver (Steatosis) | Alcoholic Liver Disease | Alcoholic fatty liver (AFL) is the earliest and most common manifestation of alcohol-related liver disease, characterized by accumulation of triglycerides within hepatocytes (macrovesicular steatosis) resulting from ethanol metabolism. Alcohol oxidation by alcohol dehydrogenase and CYP2E1 generates excess NADH, shifting the hepatic redox state to favor fatty acid synthesis (via SREBP-1c upregulation) and inhibit fatty acid beta-oxidation. Acetaldehyde, the primary toxic metabolite, damages mitochondria and impairs VLDL secretion, further promoting fat accumulation. AFL develops in approximately 90% of individuals consuming >40g/day of alcohol (women) or >60g/day (men) and is fully reversible with abstinence. | AFL is present in approximately 90% of heavy drinkers. Alcohol use disorder affects approximately 15 million adults in the United States, with alcohol-related liver disease (ALD) affecting approximately 2-3% of the general population. ALD accounts for approximately 50% of cirrhosis-related deaths in the US and Europe. The global burden is increasing, particularly in low- and middle-income countries with rising alcohol consumption. | AFL can develop at any age in individuals with significant alcohol consumption, typically after years of regular heavy drinking. Most commonly presents in adults aged 30-60 years. Women develop AFL at lower alcohol intake thresholds due to lower gastric alcohol dehydrogenase activity, higher body fat percentage, and estrogen-mediated effects on alcohol metabolism. Genetic factors (PNPLA3, TM6SF2 variants) influence susceptibility. | Most patients with AFL are asymptomatic or have nonspecific symptoms such as mild fatigue, malaise, and vague right upper quadrant discomfort. Hepatomegaly is the most common physical finding, present in 50-70% of cases. Laboratory findings include mildly elevated GGT (the most sensitive marker), mild AST and ALT elevation (typically <5x ULN) with AST/ALT ratio >1 (reflecting mitochondrial injury and pyridoxal-5-phosphate deficiency). Macrocytosis (elevated MCV) from folate deficiency and direct alcohol toxicity on erythropoiesis is common. | Liver (hepatocytes with macrovesicular steatosis, predominantly centrilobular/zone 3) | Diagnosis is based on history of significant alcohol consumption combined with imaging evidence of hepatic steatosis. Ultrasound shows hyperechoic liver (bright liver) with sensitivity of 60-94% for moderate-severe steatosis. CT shows decreased hepatic attenuation relative to spleen. MRI with proton density fat fraction (PDFF) is the most accurate non-invasive method for quantifying steatosis. Liver biopsy shows macrovesicular steatosis predominantly in zone 3 (pericentral) hepatocytes. Biomarkers of alcohol use (phosphatidylethanol, carbohydrate-deficient transferrin, ethyl glucuronide) help confirm alcohol exposure. | Complete alcohol abstinence is the cornerstone of treatment and is curative, with resolution of steatosis typically within 2-6 weeks. Nutritional support including thiamine supplementation (100-250mg/day), folate, and a balanced diet is essential, as malnutrition is common in heavy drinkers. No pharmacologic therapy is specifically indicated for isolated AFL. Behavioral interventions including motivational interviewing, cognitive-behavioral therapy, and pharmacotherapy for alcohol use disorder (naltrexone, acamprosate, disulfiram) support sustained abstinence. Brief intervention counseling by primary care providers reduces alcohol consumption by 20-30%. | Good - AFL is completely reversible with alcohol abstinence within 2-6 weeks. With continued drinking, approximately 10-35% progress to alcoholic steatohepatitis (ASH) and 8-20% develop cirrhosis over 10-20 years. Risk factors for progression include female sex, obesity, genetic susceptibility (PNPLA3 I148M), continued heavy drinking, and concurrent hepatitis C infection. Without abstinence, mortality from all-cause ALD is significantly elevated compared to the general population. | K70.0 |
| 24 | 22 | Alcoholic Fibrosis | Alcoholic Liver Disease | Alcoholic fibrosis represents the intermediate stage between alcoholic steatohepatitis and established cirrhosis, characterized by progressive deposition of extracellular matrix (collagen types I and III) in the hepatic parenchyma. Ethanol and acetaldehyde directly activate hepatic stellate cells (the principal fibrogenic cells) to transform into myofibroblasts that produce collagen, while Kupffer cell-derived TGF-beta, PDGF, and CTGF amplify fibrogenesis. A distinctive pattern is perisinusoidal (pericellular/chicken-wire) fibrosis in zone 3, which is highly characteristic of alcohol-related liver injury. Progressive fibrosis leads to architectural distortion, nodule formation, and eventually established cirrhosis. | Among heavy drinkers, approximately 20-40% develop significant fibrosis, with 10-20% progressing to cirrhosis. Risk factors for fibrosis progression include female sex, obesity, daily amount of alcohol consumed (>60g/day markedly increases risk), PNPLA3 I148M polymorphism, concurrent hepatitis C, and iron overload. The prevalence of significant fibrosis among heavy drinkers is higher than previously estimated, as many patients are asymptomatic and undiagnosed. | Alcoholic fibrosis typically develops after 10-20 years of heavy alcohol consumption, most commonly presenting in adults aged 40-60 years. The rate of fibrosis progression varies widely between individuals, with some developing cirrhosis within 5 years and others remaining stable for decades. Women progress faster at lower alcohol intake than men. | Most patients with alcoholic fibrosis are asymptomatic or have nonspecific symptoms (fatigue, mild abdominal discomfort). Physical examination may reveal hepatomegaly. Laboratory findings are nonspecific: mildly elevated AST and GGT, with normal or mildly elevated ALT. Thrombocytopenia (platelet count <150,000) may be an early indicator of advancing fibrosis and portal hypertension. As fibrosis progresses toward cirrhosis, signs of portal hypertension (splenomegaly, varices) begin to develop. | Liver (perisinusoidal fibrosis, perivenular fibrosis, and eventually bridging fibrosis with architectural distortion) | Non-invasive fibrosis assessment is the primary diagnostic approach: transient elastography (FibroScan) with liver stiffness values >7.1 kPa suggesting significant fibrosis and >12.5 kPa suggesting cirrhosis (values may be falsely elevated in acute alcoholic hepatitis or steatosis). Serum biomarkers include FIB-4 index, APRI, Enhanced Liver Fibrosis (ELF) test, and FibroTest. Liver biopsy is the gold standard and shows characteristic perisinusoidal/pericellular fibrosis, with staging by Metavir or Ishak systems. Fibrosis assessment should be performed after a period of abstinence (ideally 2-4 weeks) as inflammation can overestimate fibrosis by elastography. | Alcohol abstinence is the most effective intervention and can lead to significant fibrosis regression. Nutritional optimization with adequate protein and calorie intake. No FDA-approved antifibrotic therapy exists, though clinical trials are ongoing (cenicriviroc, obeticholic acid, simtuzumab). Management of alcohol use disorder is essential. Monitoring for progression to cirrhosis with annual non-invasive fibrosis assessment. Treatment of cofactors that accelerate fibrosis (obesity, hepatitis C, iron overload, metabolic syndrome). | Moderate - With sustained abstinence, fibrosis regression is possible and has been demonstrated histologically in multiple studies, particularly in patients with perisinusoidal and early bridging fibrosis. Even advanced fibrosis (F3) can partially regress with prolonged abstinence. However, with continued drinking, progression to cirrhosis occurs in 40-60% over 10-15 years. The presence of concomitant risk factors (obesity, HCV, PNPLA3 polymorphism) accelerates progression. Regular monitoring allows early detection of progression to cirrhosis when interventions can still improve outcomes. | K70.2 |
| 25 | 23 | Alcoholic Foamy Degeneration | Alcoholic Liver Disease | Alcoholic foamy degeneration (AFD) is a rare histologic variant of acute alcohol-related liver injury characterized by diffuse microvesicular steatosis (small fat droplets that do not displace the hepatocyte nucleus), mimicking the appearance of acute fatty liver of pregnancy or valproate hepatotoxicity. The pathogenesis involves severe mitochondrial dysfunction from direct alcohol and acetaldehyde toxicity, impairing beta-oxidation of fatty acids and leading to accumulation of small lipid droplets within hepatocytes. Unlike typical alcoholic fatty liver (macrovesicular steatosis), AFD represents more severe mitochondrial injury and can be associated with lactic acidosis and liver failure. It may coexist with other features of alcoholic liver disease including Mallory-Denk bodies and neutrophilic infiltration. | AFD is rare and probably underdiagnosed, with fewer than 100 well-documented cases in the literature. It may be more common than recognized because liver biopsy is not routinely performed in patients with alcoholic liver disease. The exact prevalence among heavy drinkers is unknown but is estimated at less than 1% of ALD presentations. | Typically presents in adults aged 30-60 years with heavy chronic alcohol use and often a recent episode of particularly heavy binge drinking. Both men and women are affected. May present acutely mimicking other causes of microvesicular steatosis. | Presentation ranges from asymptomatic with isolated laboratory abnormalities to fulminant hepatic failure. Typical symptoms include jaundice, fatigue, anorexia, nausea, and right upper quadrant pain. Laboratory findings include elevated transaminases (often modest), elevated bilirubin, and potentially lactic acidosis (from mitochondrial dysfunction). Severe cases may present with coagulopathy and encephalopathy. The clinical picture may mimic acute fatty liver of pregnancy, Reye syndrome, or drug-induced microvesicular steatosis. | Liver (hepatocytes with diffuse microvesicular steatosis from mitochondrial dysfunction); metabolic system (lactic acidosis) | Diagnosis requires liver biopsy showing diffuse microvesicular steatosis (small fat droplets with centrally placed nucleus, foamy cytoplasm) confirmed by oil-red-O staining on frozen sections. The histologic pattern distinguishes AFD from typical macrovesicular alcoholic steatosis. Exclusion of other causes of microvesicular steatosis is essential: pregnancy (AFLP), drugs (valproate, tetracycline, nucleoside analogues), Reye syndrome, and inborn errors of fatty acid oxidation. Electron microscopy shows swollen, structurally abnormal mitochondria. | Alcohol abstinence is the primary treatment and is essential for recovery. Supportive care with nutritional support, thiamine supplementation, and management of metabolic derangements (lactic acidosis correction). In severe cases with liver failure, intensive care with monitoring for coagulopathy, encephalopathy, and multiorgan dysfunction. Liver transplantation may be considered for fulminant cases not responding to supportive care. | Variable - Mild cases of AFD resolve completely with abstinence over 2-4 weeks. Severe cases with liver failure have significant mortality (case fatality rate of approximately 25% in early case series). The prognosis is better than initially reported, likely because mild cases were underdiagnosed. Long-term prognosis depends on the degree of underlying chronic liver disease and sustained abstinence. | K70.0 |
- Full dataset access
- Excel format
- Instant download